[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 220
1. Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY: Oxaliplatin-related acute myelogenous leukemia. Oncologist; 2006 Mar;11(3):261-2
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-related acute myelogenous leukemia.
  • Bone marrow biopsy was consistent with therapy-related acute myelogenous leukemia.
  • It is likely that the leukemia was related to the oxaliplatin administration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Cecal Neoplasms / drug therapy. Cecal Neoplasms / pathology. Chromosome Deletion. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Middle Aged. Omentum / pathology. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / secondary. Trisomy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549810.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 2S9ZZM9Q9V / Bevacizumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


2. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients.
  • Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient.
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


3. Funk RK, Maxwell TJ, Izumi M, Edwin D, Kreisel F, Ley TJ, Cheverud JM, Graubert TA: Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice. Blood; 2008 Aug 15;112(4):1434-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice.
  • Therapy-related acute myelogenous leukemia (t-AML) is an important late adverse effect of alkylator chemotherapy.
  • Susceptibility to t-AML has a genetic component, yet specific genetic variants that influence susceptibility are poorly understood.
  • We analyzed an F(2) intercross (n = 282 mice) between mouse strains resistant or susceptible to t-AML induced by the alkylator ethyl-N-nitrosourea (ENU) to identify genes that regulate t-AML susceptibility.
  • Each mouse carried the hCG-PML/RARA transgene, a well-characterized initiator of myeloid leukemia.
  • In the absence of ENU treatment, transgenic F(2) mice developed leukemia with higher incidence (79.4% vs 12.5%) and at earlier time points (108 days vs 234 days) than mice in the resistant background.
  • Thirteen QTLs significantly associated with leukemia-free survival, spleen weight, or white blood cell count were identified on 8 chromosomes.
  • These results suggest that susceptibility to ENU-induced leukemia in mice is a complex trait governed by genes at multiple loci.
  • Improved understanding of genetic risk factors should lead to tailored treatment regimens that reduce risk for patients predisposed to t-AML.

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15103-8 [10611345.001]
  • [Cites] Leukemia. 2005 Nov;19(11):1919-28 [16167058.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):109-17 [11225603.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):255-76 [11378539.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5029-38 [16707424.001]
  • [Cites] Heredity (Edinb). 1992 Oct;69(4):315-24 [16718932.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):59-70 [17143301.001]
  • [Cites] Br J Haematol. 2007 Feb;136(4):590-6 [17367411.001]
  • [Cites] Br J Haematol. 2007 Jun;137(6):513-29 [17539774.001]
  • [Cites] Br J Radiol. 2007 Sep;80 Spec No 1:S56-62 [17704327.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8281-6 [11781843.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1972-6 [12200354.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] Exp Toxicol Pathol. 2002 Nov;54(3):193-6 [12484555.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2015-23 [12393427.001]
  • [Cites] Bioinformatics. 2003 May 1;19(7):889-90 [12724300.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Leukemia. 2004 Jan;18(1):120-5 [14586477.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] Genetics. 1989 Jan;121(1):185-99 [2563713.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Mutat Res. 1994 Apr 1;306(1):19-34 [7512200.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1063-73 [8164031.001]
  • [Cites] Leuk Lymphoma. 1996 Feb;20(5-6):365-72 [8833391.001]
  • [Cites] Blood. 1997 Jan 15;89(2):376-87 [9002938.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1438-46 [9083167.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2199-204 [9395034.001]
  • [Cites] Genet Res. 1997 Oct;70(2):117-24 [9449188.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] N Engl J Med. 2004 Dec 2;351(23):2403-7 [15575056.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):482-93 [15534356.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:187-95 [15935816.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12513-8 [16113082.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):531-43 [11181704.001]
  • (PMID = 18552208.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA101937; United States / NCI NIH HHS / CA / P30 CA091842; United States / NIDDK NIH HHS / DK / T35 DK074375; United States / NCI NIH HHS / CA / P30 CA91842
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • [Other-IDs] NLM/ PMC2515115
  •  go-up   go-down


Advertisement
4. Klepin HD, Balducci L: Acute myelogenous leukemia in older adults. Oncologist; 2009 Mar;14(3):222-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia in older adults.
  • The incidence of acute myelogenous leukemia (AML) increases with age.
  • Older AML patients, generally defined by age > or = 60 years, have worse treatment outcomes than younger patients.
  • While selected older patients can benefit from standard therapies, as a group they experience greater treatment-related toxicity, lower remission rates, shorter disease-free survival times, and shorter overall survival times.
  • Outcome disparity is in part explained by age-related biologic features.
  • Older patients are more likely to present with unfavorable cytogenetic abnormalities, multidrug resistance phenotypes, and secondary AML.
  • Investigations of hypomethylating agents and signal transduction inhibitors hold promise for the treatment of AML patients.
  • [MeSH-major] Geriatrics / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282349.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


5. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, Forman S, Bhatia S, Bhatia R: Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol; 2009 Feb 10;27(5):791-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
  • PURPOSE: Therapy-related myelodysplasia or acute myelogenous leukemia (t-MDS/AML) is a lethal complication of autologous hematopoietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).
  • Here, we investigated the hypothesis that accelerated telomere shortening after aHCT could contribute to the development of t-MDS/AML.
  • PATIENTS AND METHODS: A prospective longitudinal cohort was constructed to investigate the sequence of cellular and molecular abnormalities leading to development of t-MDS/AML after aHCT for HL/NHL.
  • This cohort formed the sampling frame for a nested case-control study to compare changes in telomere length in serial blood samples from patients who developed t-MDS/AML with matched controls who did not develop t-MDS/AML.
  • RESULTS: An initial increase in telomere length at day 100 after aHCT was followed by an accelerated telomere shortening in t-MDS/AML patients when compared with controls.
  • These telomere alterations preceded the onset of t-MDS and were independent of other known risk factors associated with development of t-MDS/AML on multivariate analysis.
  • Additionally, we observed reduced generation of committed progenitors in patients who developed t-MDS/AML, indicating that these telomere alterations were associated with reduced regenerative capacity of hematopoietic stem cells.
  • CONCLUSION: The development of t-MDS/AML after aHCT is associated with and preceded by markedly altered telomere dynamics in hematopoietic cells.
  • Accelerated telomere loss in patients developing t-MDS/AML may reflect increased clonal proliferation and/or altered telomere regulation in premalignant cells.
  • Genetic instability associated with shortened telomeres may contribute to leukemic transformation in t-MDS/AML.


6. Borthakur G, Estey AE: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep; 2007 Sep;9(5):373-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
  • Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/MDS) are increasing in prevalence with aging of the population and improved survival of patients treated with chemotherapy or radiotherapy for other malignancies.
  • Research focused on the pathogenesis of t-AML/MDS will provide insight into the pathogenesis of de novo AML/MDS.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Humans. Neoplasms / drug therapy. Prognosis


7. Faller BA, Robu VG, Borghaei H: Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer. Clin Lung Cancer; 2009 Nov;10(6):438-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia with an 11q23/MLL translocation following adjuvant cisplatin and vinorelbine for non-small-cell lung cancer.
  • We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC.
  • To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination.
  • The literature on t-AML with the 11q23/MLL rearrangement is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Translocation, Genetic / drug effects
  • [MeSH-minor] Aged. Carcinoma, Non-Small-Cell Lung / drug therapy. Chromosomes, Human, Pair 11. Cisplatin / administration & dosage. Follow-Up Studies. Histone-Lysine N-Methyltransferase. Humans. Lung Neoplasms / drug therapy. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives


8. Betancourt-García RD, Castro J, Fernández AC, López-Enríquez A, Fradera J, Pacheco E: Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature. P R Health Sci J; 2009 Jun;28(2):146-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
  • Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myelogenous leukemia (t-AML) in patients with acute promyelocytic leukemia (APL) are rare events.
  • The cumulative exposure to chemotherapy with alkylating agents and topoisomerase II inhibitors is associated with t-AML that may develop any time after the completion of the treatment.
  • We report the case of an acquired AML who previously received therapy for APL, after two years of being diagnosed.
  • The diagnosis was established by morphologic findings, membrane markers, cytogenetic studies, and fluorescence in situ hybridization (FISH).
  • To our knowledge this is the first documented case in Puerto Rico of a patient with APL that developed a t-AML without the characteristic chromosomal and morphologic findings of APL.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasms, Second Primary / etiology. Translocation, Genetic


9. Pyatt DW, Aylward LL, Hays SM: Is age an independent risk factor for chemically induced acute myelogenous leukemia in children? J Toxicol Environ Health B Crit Rev; 2007 Sep-Oct;10(5):379-400
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is age an independent risk factor for chemically induced acute myelogenous leukemia in children?
  • Secondary or therapy-related acute myelogenous leukemia (t-AML) is a rare but unfortunate consequence of treatment with certain classes of cytotoxic chemotherapeutic agents or chronic exposure to high concentrations of benzene.
  • Drugs known to produce AML following chemotherapy of primary malignancy are usually alkylating agents or topoisomerase II inhibitors.
  • Both children and adults develop AML following treatment with these classes of antineoplastic drugs.
  • In this review, the effect of age at treatment on a child's susceptibility to developing therapy related AML was investigated.
  • As demonstrated in the published literature, the risk of developing AML following chemotherapy is not reliably correlated with the age of the pediatric patient.
  • The age dependency of treatment-related malignancies (all types) in children appears to vary considerably with the type of secondary neoplasm in question.
  • For example, secondary solid tumors such as breast, central nervous system (CNS), bone, and thyroid cancer are highly dependent on the age of the patient at time of diagnosis and treatment; in contrast, an age dependency for t-AML risk was not observed in these same patient populations.
  • Predictably, the induction of t-AML in children follows a rational dose-response relationship, with increasing doses of chemotherapy resulting in greater risk. Recent U.S.
  • Available scientific and medical literature does not support the hypothesis that children necessarily possess an increased risk of developing AML following leukemogenic chemical exposure.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / epidemiology. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687725.001).
  • [ISSN] 1521-6950
  • [Journal-full-title] Journal of toxicology and environmental health. Part B, Critical reviews
  • [ISO-abbreviation] J Toxicol Environ Health B Crit Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Topoisomerase II Inhibitors
  • [Number-of-references] 92
  •  go-up   go-down


10. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O: Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet; 2005 Mar;157(2):104-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
  • The BCR/ABL tyrosine kinase inhibitor imatinib has shown remarkable efficacy in treating patients with chronic myelogenous leukemia (CML).
  • Leukemic cells from the patient were found to express the fusion transcript of NUP98 and DDX10, which is in accordance with previously reported cases of de novo or therapy-related acute myelogenous leukemia and myelodysplastic syndrome with inv(11)(p15q22).
  • These observations raise a possibility that the NUP98/DDX10 fusion might be involved in imatinib resistance as well as in acute transformation of CML.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 11. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721630.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Nuclear Pore Complex Proteins; 0 / Nup98 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 0 / nuclear pore complex protein 98; 8A1O1M485B / Imatinib Mesylate; EC 3.6.1.- / DDX10 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases; EC 3.6.4.13 / RNA Helicases
  •  go-up   go-down


11. Gotlib J: Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep; 2005 Jan;4(1):77-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
  • Acute myelogenous leukemia (AML) remains a clinical challenge with poor long-term survival.
  • Low remission rates and high treatment-related mortality persist as major obstacles, particularly in older patients.
  • The preclinical concept of farnesyltransferase blockade as a targeted therapy against oncogenic Ras has clearly evolved with the recognition that many proteins involved signaling pathways in tumor cells undergo farnesylation.
  • Phase I/II trials of FTI monotherapy in AML demonstrate encouraging responses and good tolerability.
  • The FTI tipifarnib (R115777, Zarnestra; Johnson & Johnson, Titusville, NJ) has advanced the furthest in clinical trials, with the most promising activity in previously untreated, high-risk AML patients.
  • Preclinical concepts related to the development of FTIs, the rationale for their use in AML, and efficacy and safety results from recent clinical trials are evaluated in this paper.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Farnesyltranstransferase / antagonists & inhibitors. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. Clinical Trials as Topic. Cohort Studies. Hematopoiesis / drug effects. Humans. Multicenter Studies as Topic. Neoplasm Proteins / drug effects. Neoplasm Proteins / metabolism. Protein Prenylation / drug effects. Protein Processing, Post-Translational / drug effects. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / drug effects. Signal Transduction / drug effects. Treatment Outcome. ras Proteins / physiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610664.001).
  • [ISSN] 1541-0714
  • [Journal-full-title] Current hematology reports
  • [ISO-abbreviation] Curr. Hematol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Receptors, Transforming Growth Factor beta; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 66
  •  go-up   go-down


12. Tsujimura H, Mimura N, Ise M, Sakai C, Shimada H, Nagata M, Kumagai K: Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer.
  • On the other hands, a sufficiently long survival time has increased treatment-related late toxicities.
  • RESULTS: Four patients, who achieved CR after CRT, developed leukemia.
  • Case1, 60-yo-male, developed overt acute myeloid leukemia (AML) from myelodysplastic syndrome 48 months after CRT.
  • Case2, 64-yo-male, developed AML M0 with t(9;22)(q34;q11) 44 months after CRT.
  • Case3, 72-yo-male, developed Burkitt leukemia with t(8;14)(q24;q32) 19 months after CRT.
  • Case4, 65-yo-male, developed myeloid crisis of chronic myelogenous leukemia with complicated abnormalities including t(9;22)(q34;q11) 48 months after CRT.
  • All patients eventually died of leukemia.
  • To this end, atypical cytogenetic abnormalities seen in the present cases give a new insight into the biology of therapy-related leukemia.
  • Notably, this is the first report presenting the incidence of secondary leukemia by nedaplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Luger SM: Treating the elderly patient with acute myelogenous leukemia. Hematology Am Soc Hematol Educ Program; 2010;2010:62-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating the elderly patient with acute myelogenous leukemia.
  • Decisions regarding the optimal treatment of acute myelogenous leukemia in the elderly patient requires the consideration of multiple factors.
  • Population-based studies have demonstrated that, for all age groups, aggressive therapy results in improved survival and quality of life when compared with palliative care.
  • Furthermore, not all patients are candidates for such therapy.
  • Consideration of patient and disease-related factors can help to determine the appropriateness of intensive therapy in a given patient.
  • For those patients for whom aggressive induction therapy does not seem to be in their best interest, novel agents are being investigated that will hopefully address the issues of induction death and early relapse associated with these patient populations.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239772.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Ciurea SO, Rodrigues M, Giralt S, de Lima M: Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence? Clin Lymphoma Myeloma; 2009 Aug;9(4):289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?
  • Acute myelogenous leukemia is a disease of the elderly.
  • Disease biology and functional status of this patient population contribute to poorer treatment outcomes with standard therapy.
  • However, transplantation was restricted until recently to younger patients because of prohibitive treatment-related mortality.
  • The development of reduced-intensity preparative regimens and improvements in supportive care now allow older patients with myeloid leukemia a greater opportunity for cure with transplantation.
  • [MeSH-major] Aging / physiology. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy


15. Bhojwani D, Moskowitz N, Raetz EA, Carroll WL: Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia. Paediatr Drugs; 2007;9(3):149-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.
  • Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous disease.
  • Current treatment approaches are tailored according to the clinical features of the host, genotypic features of the leukemic blast, and early response to therapy.
  • Additional promising utilities include prediction of early response to therapy, overall outcome, and adverse effects.
  • Identification of patients who are predicted to have an unfavorable outcome may allow for early intervention such as intensification of therapy or avoidance of drugs that are associated with specific secondary effects such as therapy-related acute myelogenous leukemia.
  • These newer methods of genome analyses complemented by studies involving the proteome as well as host polymorphisms will have a profound impact on the diagnosis and management of childhood ALL.
  • [MeSH-major] Gene Expression Profiling. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523695.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114762
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Oncogene Proteins
  • [Number-of-references] 36
  •  go-up   go-down


16. Podgornik H, Debeljak M, Zontar D, Cernelc P, Prestor VV, Jazbec J: RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia. Cancer Genet Cytogenet; 2007 Oct 1;178(1):77-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 amplification in lineage conversion of childhood B-cell acute lymphoblastic leukemia to acute myelogenous leukemia.
  • Amplification of RUNX1 (alias AML1) is a recurrent karyotypic abnormality in childhood acute lymphoblastic leukemia (ALL) that is generally associated with a poor outcome.
  • It does not occur with other primary chromosomal abnormalities in acute ALL.
  • AML1 amplification in acute myelogenous leukemia (AML) is a rare secondary event described mainly in therapy-related cases.
  • AML1 amplification was found in a 13-year-old patient with AML M4/M5 leukemia that occurred 5 years after she had been diagnosed with common B-cell ALL.
  • Conventional cytogenetic, fluorescent in situ hybridization (FISH), and polymerase chain reaction methods revealed no other chromosomal change expected to occur in a disease that we assumed to be a secondary leukemia.
  • This analysis confirmed that in addition to t(12;21), AML1 amplification and overexpression existed already at the time the diagnosis was made.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / genetics. Leukemia, B-Cell / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology


17. Malaise M, Steinbach D, Corbacioglu S: Clinical implications of c-Kit mutations in acute myelogenous leukemia. Curr Hematol Malig Rep; 2009 Apr;4(2):77-82
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of c-Kit mutations in acute myelogenous leukemia.
  • Aberrantly activated RTK and related downstream signaling partners were identified as key elements in the molecular pathogenesis of several malignancies.
  • This finding culminated in a two-class model integrating constitutive activating and maturation arrest-inducing mutations as key elements for the pathogenesis of acute myelogenous leukemia (AML).
  • c-Kit is expressed by myeloblasts in about 60% to 80% of patients, and the most frequently observed activating RTK mutations in AML (next to FLT3) are mutations or internal tandem duplications in c-Kit, with an overall incidence of 17%.
  • The identification of small-molecule tyrosine kinase inhibitors capable of blocking key kinase switches introduced a paradigm change in the treatment of diseases like gastrointestinal stromal tumors and chronic myelogenous leukemia.
  • Despite encouraging preclinical data, it appears that a complex clonal disease like AML will probably benefit from a synergistic approach of targeted drugs used (at least for now) in combination with conventional chemotherapy.
  • [MeSH-major] Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics. Mutation. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gene Expression Regulation, Leukemic. Humans. Prognosis. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425418.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 53
  •  go-up   go-down


18. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol; 2007 Sep 20;25(27):4285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
  • PURPOSE: To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy.
  • PATIENTS AND METHODS: Analysis of the incidence of t-MDS and t-AML in 746 patients with non-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compassionate-use trials between 1996 and 2002.
  • RESULTS: Nineteen patients (2.5%) developed t-MDS or t-AML at a median follow-up of 4.4 years (range, 0 to 9.3).
  • These malignancies were diagnosed at a median of 5.6 years (range, 1.4 to 13.9) after the diagnosis of NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy.
  • The annualized rates were 0.3% per year after the diagnosis of NHL and 0.7% per year after treatment.
  • Most patients with t-MDS or t-AML had multiple cytogenetic aberrations, commonly on chromosomes 5 and 7, suggesting an association with previous exposure to chemotherapy.
  • CONCLUSION: Analysis of data from patients in registration and compassionate-use trials suggests that the annualized incidences of t-MDS and t-AML are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen.
  • Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abnormalities in previously treated patients, particularly those who have been treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS or t-AML.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Leukemia, Myeloid, Acute / etiology. Lymphoma, Non-Hodgkin / therapy. Myelodysplastic Syndromes / etiology. Radioimmunotherapy / methods. Yttrium Radioisotopes / administration & dosage. Yttrium Radioisotopes / adverse effects


19. Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H: Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer; 2009 Jul 15;115(14):3217-21
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
  • BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor.
  • The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML.
  • Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.
  • METHODS: A total of 188 patients with CBF AML were analyzed.
  • The frequency of secondary CBF AML was 9%.
  • RESULTS: Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML.
  • Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.
  • CONCLUSIONS: Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
  • [MeSH-major] Core Binding Factors / metabolism. Leukemia, Myeloid, Acute / mortality. Neoplasms, Second Primary / mortality

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1735-40 [10557046.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):517-23 [18297529.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):395-400 [11921273.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):143-54 [12930314.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4413-22 [14645432.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1087-94 [15020610.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] Science. 1993 Aug 20;261(5124):1041-4 [8351518.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2370-9 [8246025.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1890-6 [9586906.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 2007 Apr;21(4):725-31 [17287858.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):379-94 [11921272.001]
  • (PMID = 19441109.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factors; 04079A1RDZ / Cytarabine
  • [Other-IDs] NLM/ NIHMS629439; NLM/ PMC4184418
  •  go-up   go-down


20. de Lima M, Giralt S: Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol; 2006 Apr;43(2):107-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
  • Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) are diseases of the elderly.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the possibility of cure for these malignancies, but until recently its use was restricted to younger patients due to prohibitive treatment-related mortality.
  • Here we review current results of allogeneic blood and marrow transplantation for AML and MDS in the elderly.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy


21. Park TS, Choi JR, Yoon SH, Song J, Kim J, Kim SJ, Kwon O, Min YH: Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript. Cancer Genet Cytogenet; 2008 Dec;187(2):61-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
  • Acute promyelocytic leukemia (APL) is a subtype of acute myelogenous leukemia (AML) that is characterized by peculiar clinical and biologic features, including severe hemorrhagic diathesis, specific recurrent chromosomal aberration, and distinct morphologic features with predominant pathologic promyelocytes.
  • A reciprocal translocation involving chromosomes 15 and 17, t(15;17)(q22;q21), is a characteristic feature of APL that represents approximately 5-8% of AML.
  • In contrast to other AML subtypes, APL is particularly sensitive to treatment with all trans-retinoic acid (ATRA) combined with chemotherapy, converting this once fatal leukemia to a highly curable disease.
  • Nonetheless, therapy-related myelodysplastic syndrome-acute myelogenous leukemia (t-MDS/AML) has been reported as a rare complication of chemotherapy in APL.
  • Of 30 APL cases described as t-MDS/AML in the literature, only 1 case relapsed as acute leukemia with t(3;21)(q26;q22).
  • Here we describe a rare case of APL relapsing as secondary AML with t(3;21)(q26;q22) and clinically characterize this patient using the RUNX1 (previously AML1)-MDS1-EVI1 fusion transcript (with follow-up for 55 months), and review the relevant literature.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Neoplasms, Second Primary / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027486.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; 0 / Transcription Factors; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin
  •  go-up   go-down


22. Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC: Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol; 2007 Jul;18(7):1246-52
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.
  • BACKGROUND: Curative intent chemotherapy for acute myelogenous leukemia (AML) leads to prolonged severe neutropenia, during which patients are highly susceptible to infection.
  • Our center recently implemented a selective ambulatory management policy for AML patients undergoing chemotherapy.
  • MATERIALS AND METHODS: A retrospective analysis was conducted to assess the occurrence of septicemia in AML patients treated over a 5 years period with curative intent chemotherapy.
  • This review encompasses a change in policy from primarily inpatient care to selective outpatient management coupled with prophylactic antibiotic therapy.
  • No significant emerging resistance and no septicemia-related mortality were noted in the outpatient cohort.
  • CONCLUSION: The observed decrease in the incidence of septicemia in the ambulatory cohort adds supportive evidence to the feasibility of selective outpatient management of AML patients with respect to infectious complications.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442662.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF: Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol; 2010;3:36
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.
  • Optimal conditioning therapy for hematopoietic cell transplantation (HCT) in acute myelogenous leukemia (AML) remains undefined.
  • We retrospectively compared outcomes of a consecutive series of 51 AML patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg IV × 2 days) - (Bu/Cy) with 100 consecutive AML patients treated with pharmacokinetic targeted IV busulfan (AUC < 6000 μM/L*min per day × 4 days) and fludarabine (40 mg/m2 × 4 days) - (t-IV Bu/Flu).
  • Pharmacokinetic targeting of intravenous busulfan in combination with fludarabine is associated with reduced conditioning regimen related toxicity compared to oral busulfan and cyclophosphamide.
  • [MeSH-major] Busulfan / pharmacokinetics. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):468-76 [12374451.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69 [19611402.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(12):1089-95 [12796788.001]
  • [Cites] Blood. 2003 Aug 1;102(3):820-6 [12676781.001]
  • [Cites] Blood. 2004 Aug 1;104(3):857-64 [15073038.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):255-67 [8420443.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 1996 Feb;17(2):225-30 [8640171.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3599-604 [9808553.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5728-38 [16009946.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5675-87 [16110027.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1931-8 [16178004.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9387-93 [16314618.001]
  • [Cites] Leukemia. 2006 Feb;20(2):322-8 [16307018.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1092-9 [16551971.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):541-7 [17637692.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):577-84 [18086801.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(8):721-7 [18176613.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jun;14(6):672-84 [18489993.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):993-1003 [18721762.001]
  • [Cites] Blood. 2003 Mar 1;101(5):2043-8 [12406916.001]
  • (PMID = 20925957.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2958877
  •  go-up   go-down


24. Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX: [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia]. Ai Zheng; 2006 Aug;25(8):1007-12
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
  • BACKGROUND & OBJECTIVE: The manifestations of old acute myelogenous (AML) patients have their special biological and clinical characteristics, with lower response rate to therapy and shorter survival time.
  • This study was to investigate the prognostic factors of elderly patients with AML retrospectively.
  • METHODS: 77 patients aged> or =60 years with AML from 1994 to 2005 were admitted to our study and all the possible prognostic factors were analyzed with Kaplan-Meier survival analysis.
  • The patients with primary AML (median survival time was 98 days) had significantly longer survival time than those with secondary AML (median survival time was 32 days)(P=0.007), which their CR ratios were 50% and 0% (P=0.023).
  • The patients received chemotherapy (50%) had significantly higher CR ratio than those received supportive therapy (0%)(P=0.001).
  • In the stepwise COX proportional hazard regression model, all the seven factors related to OS remained independent and significant.
  • CONCLUSIONS: Factors, including age >70, PS 2 to 4, percentage of blasts in bone marrow >50%, secondary AML, unfavorable karyotype, expression of CD34, lower dosage.
  • [MeSH-major] Anthracyclines / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965684.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antigens, CD34
  •  go-up   go-down


25. Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S, Kasahara S, Sato A, Monma F, Nagamura F, Iseki T, Tojo A, Asano S: Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biol Blood Marrow Transplant; 2008 Dec;14(12):1341-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia.
  • We analyzed the disease-specific outcomes of adult acute myelogenous leukemia (AML) patients treated with unrelated cord blood transplantation (CBT) after myeloablative conditioning.
  • Between August 1998 and February 2008, 77 adult patients with AML were treated with unrelated CBT.
  • The cumulative incidence of grade III to IV acute graft-versus-host disease (aGVHD) and extensive-type chronic GVHD (cGVHD) was 25.1% and 28.6%, respectively.
  • The 5-year cumulative incidence of treatment related-mortality (TRM) and relapse was 9.7%, 25.8%, respectively.
  • These results suggest that unrelated CBT after myeloablative conditioning could be safely and effectively used for adult patients with AML.
  • [MeSH-major] Cord Blood Stem Cell Transplantation. HLA Antigens. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antigens, CD34. Disease-Free Survival. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Incidence. Male. Middle Aged. Neutrophils. Recovery of Function. Survival Rate. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041055.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / HLA Antigens
  •  go-up   go-down


26. Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol; 2006 Aug 1;24(22):3604-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
  • PURPOSE: The risk factors for treatment-related myelodysplastic syndrome (t-MDS) and acute myelogenous leukemia (AML) after autologous stem-cell transplantation (ASCT) are similar to those that increase the risk of difficult stem-cell harvests.
  • We reviewed our experience in 526 patients with lymphoma treated by ASCT to determine whether difficult stem-cell harvests predict for an increased risk of t-MDS/AML.
  • RESULTS: With a median follow-up time for surviving patients of 69 months, 20 patients developed t-MDS/AML, for an actuarial incidence of 6.8% at 10 years.
  • Pretransplantation characteristics, including age, diagnosis of non-Hodgkin's lymphoma or Hodgkin's disease, bone marrow involvement, prior radiation therapy, prior exposure to chemotherapy, lactate dehydrogenase at the time of ASCT, disease status, and method of stem-cell mobilization, were then analyzed with respect to the subsequent development of t-MDS/AML.
  • By multivariable analysis, prior exposure to radiation therapy, four or more chemotherapy regimens, and more than 5 days of apheresis needed to harvest enough stem cells were identified as independent risk factors for t-MDS/AML.
  • CONCLUSION: These results suggest that identifiable pretransplantation factors predict for t-MDS/AML after ASCT.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Lymphoma / surgery. Myelodysplastic Syndromes / etiology. Peripheral Blood Stem Cell Transplantation


27. Petersen FB, Ford CD: Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S7-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia.
  • Dose-intense conditioning (DIC) (myeloablative) regimens for allogeneic stem cell transplantation (alloSCT) were previously avoided in patients with acute myelogenous leukemia aged more than 55 years because of the fear of excessive morbidity and mortality.
  • Significant disadvantages remain, however, including the late establishment of a posttransplant graft-versus-leukemia effect and an overrepresentation of poor prognostic factors in elderly patients, resulting in the risk of early relapse/progression before the graft-versus-leukemia effect being disproportionally large.
  • We hypothesize that DIC may be important for the early control of leukemia in elderly patients, and that prospective, randomized trials comparing DIC and RIC-based transplants should be carried out, with the expectation that early transplant-related mortality will be no different.
  • [MeSH-major] Health Services for the Aged. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561415.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


28. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM: Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res; 2008 Nov 15;68(22):9394-403
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
  • To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor.
  • Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53.
  • Perifosine also synergized with TRAIL in primary AML cells displaying constitutive activation of the Akt pathway by inducing apoptosis, Akt dephosphorylation, TRAIL-R2 up-regulation, cFLIP-L and XIAP down-regulation, and c-Jun phosphorylation.
  • The combined treatment negatively affected the clonogenic activity of CD34(+) cells from patients with AML.
  • Our findings suggest that the combination of perifosine and TRAIL might offer a novel therapeutic strategy for AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Nov 15;98(10):3058-65 [11698291.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):194-205 [17897295.001]
  • [Cites] J Cell Sci. 2002 Sep 15;115(Pt 18):3587-99 [12186945.001]
  • [Cites] Leukemia. 2003 Feb;17(2):379-89 [12592338.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):66-75 [12655296.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):713-20 [12780785.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 [12787570.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):897-910 [15019974.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2580-9 [15059915.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):333-9 [15251125.001]
  • [Cites] Cell Death Differ. 2004 Aug;11(8):897-905 [15105836.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7570-8 [15492284.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Biochem J. 1999 Feb 1;337 ( Pt 3):607-16 [9895308.001]
  • [Cites] J Immunol. 1999 May 15;162(10):6053-9 [10229846.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2747-53 [10364001.001]
  • [Cites] Curr Pharm Des. 2004;10(29):3673-81 [15579063.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2422-32 [15781658.001]
  • [Cites] Haematologica. 2005 May;90(5):612-24 [15921376.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2195-202 [16224489.001]
  • [Cites] Leukemia. 2006 Jun;20(6):911-28 [16642045.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1559-70 [16818515.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1533-40 [16341123.001]
  • [Cites] Apoptosis. 2006 Nov;11(11):1999-2011 [17013757.001]
  • [Cites] Cell Mol Life Sci. 2008 Jan;65(1):113-27 [17952368.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2392-9 [18073346.001]
  • [Cites] Oncogene. 2008 Feb 21;27(9):1273-80 [17724468.001]
  • [Cites] Free Radic Biol Med. 2008 Mar 15;44(6):1055-68 [18164688.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3742-50 [18187663.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2114-21 [17548900.001]
  • [Cites] Cell Cycle. 2007 Nov 1;6(21):2633-9 [17957143.001]
  • [Cites] Leukemia. 2008 Jan;22(1):147-60 [17928881.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1244-58 [18304628.001]
  • [Cites] Blood. 2008 May 15;111(10):5068-77 [18334673.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1106-16 [18385752.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1289-97 [16959900.001]
  • [Cites] Leukemia. 2007 Mar;21(3):427-38 [17215852.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):191-202 [17287087.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3210-9 [17409429.001]
  • [Cites] Free Radic Biol Med. 2007 May 15;42(10):1579-90 [17448905.001]
  • [Cites] Leukemia. 2007 May;21(5):886-96 [17361225.001]
  • [Cites] Curr Drug Metab. 2007 May;8(4):395-403 [17504227.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20647-56 [17504762.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2029-38 [17604333.001]
  • [Cites] J Mol Med (Berl). 2007 Sep;85(9):923-35 [17437073.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2337-45 [17699729.001]
  • [Cites] Leukemia. 2002 Jan;16(1):67-73 [11840265.001]
  • (PMID = 19010914.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098195-05; United States / NCI NIH HHS / CA / R01 CA098195-05; United States / NCI NIH HHS / CA / R01CA091025
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Proto-Oncogene Proteins c-jun; 0 / Reactive Oxygen Species; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / X-Linked Inhibitor of Apoptosis Protein; 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.13 / Protein Kinase C; EC 3.4.22.- / Caspase 8
  • [Other-IDs] NLM/ NIHMS70767; NLM/ PMC2597037
  •  go-up   go-down


29. Lichtman MA: Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? Oncologist; 2008 Jun;13(6):645-54
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
  • Advances in the therapy of malignancy have been accompanied by an increased frequency of cases of secondary acute myelogenous leukemia and related clonal cytopenias and oligoblastic (subacute) myelogenous leukemia (myelodysplastic syndromes).
  • The acute myelogenous leukemia incidence can be increased by high-dose acute ionizing radiation exposure, alkylating agents, topoisomerase II inhibitors, possibly other DNA-damaging therapeutic agents, heavy, prolonged cigarette smoking, and high dose-time exposure to benzene, the latter less frequently seen in industrialized countries with worksite regulations.
  • Acute myelogenous leukemia and myelodysplastic syndromes may result from innumerable primary types of chromosome damage.
  • In the case of chronic myelogenous leukemia, a specific break in chromosome bands 9q34 and 22q11 must occur to result in the causal fusion oncogene (BCR-ABL).
  • A review of 11 studies of the chromosomal abnormalities found in presumptive cases of cytotoxic therapy-induced leukemia and of 40 studies of the subtypes of leukemia that occur following cytotoxic therapy for other cancers has not provided evidence of an increased risk for chemically induced BCR-ABL-positive chronic myelogenous leukemia.
  • Studies of the effects of alkylating agents, topoisomerase inhibitors, and benzene on chromosomes of hematopoietic cells in vitro, coupled with the aforementioned epidemiological studies of secondary leukemia after cytotoxic therapy or of persons exposed to high dose-time concentrations of benzene in the workplace, do not indicate a relationship among chemical exposure, injury to chromosome bands 9q34 and 22q11, and an increased risk for BCR-ABL-positive chronic myelogenous leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chromosome Aberrations. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586919.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 113
  •  go-up   go-down


30. Usuki K, Nakasone H, Taoka K, Kida M, Iki S, Urabe A: [Transient chromosomal abnormalities following autologous peripheral blood stem cell transplantation for acute myelogenous leukemia]. Rinsho Ketsueki; 2007 Aug;48(8):618-23
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transient chromosomal abnormalities following autologous peripheral blood stem cell transplantation for acute myelogenous leukemia].
  • Twenty-three patients with acute myelogenous leukemia (AML) have received autologous hematopoietic stem cell transplantation (autoHSCT) in our institute from 1997 to 2005.
  • In these 4 patients with AML1/MTG8 or CBFbeta/MYH11 AML, RT-PCR findings using bone marrow cells were all negative when a cytogenetic abnormality was detected.
  • We present our finding together with a review of the literature on post-autoHSCT cytogenetic abnormalities not related to relapse or secondary leukemia/myelodysplastic syndrome.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867297.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


31. Chang PH, Lai YH, Shun SC, Lin LY, Chen ML, Yang Y, Tsai JC, Huang GS, Cheng SY: Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage; 2008 May;35(5):524-34
MedlinePlus Health Information. consumer health - Fatigue.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial.
  • The purpose of this randomized, controlled clinical trial was to preliminarily examine the effects of a three-week walking exercise program (WEP) on fatigue-related experiences of acute myelogenous leukemia (AML) patients receiving chemotherapy.
  • Eligible AML patients were randomly assigned to either an experimental group (n=11), which received 12 minutes of WEP per day, five days per week for three consecutive weeks, or to a control group (n=11), which received standard ward care.
  • Data were analyzed by Generalized Estimating Equation and revealed that AML patients in the three-week WEP group had a significantly greater increase in 12-minute walking distance than the control group.
  • Although preliminary, our results strongly suggest that three weeks of systematic walking exercise is clinically feasible for AML patients undergoing chemotherapy and can effectively improve their fatigue-related experiences.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Exercise Therapy. Fatigue / etiology. Fatigue / therapy. Leukemia, Myeloid, Acute / complications. Walking / physiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280104.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


32. Rodriguez V, Erlandson L, Arndt CA, Wiseman GA, Anderson PM: Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia. Pediatr Transplant; 2005 Feb;9(1):122-6
Hazardous Substances Data Bank. Samarium, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low toxicity and efficacy of (153)samarium-EDTMP and melphalan as a conditioning regimen for secondary acute myelogenous leukemia.
  • We report the case of a 15-yr-old girl who developed secondary acute myelogenous leukemia (AML) 4 yr after completion of therapy for metastatic Ewing sarcoma (primary right acetabulum with metastatic disease to the lungs).
  • Peripheral blood stem cells were collected after the second cycle of chemotherapy with the plan for future consolidation with high-dose chemotherapy and autologous stem cell rescue; however, because of the patient's excellent response to chemotherapy and surgery, therapy was completed without the need for high-dose chemotherapy.
  • No human leukocyte antigen (HLA)-matched related donor was available for a bone marrow transplant.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Melphalan. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Radioisotopes. Samarium. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667625.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium; Q41OR9510P / Melphalan
  •  go-up   go-down


33. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud Ø: Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets; 2005 Jun;5(4):229-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.
  • Acute myelogenous leukemia (AML) is an aggressive disorder with an overall disease-free survival of 40-50% even for the younger patients under 60 years of age who can receive the most intensive treatment.
  • The median age at the time of diagnosis is 60-65 years, and the large majority of elderly patients usually receive less intensive chemotherapy or only supportive therapy due to the high treatment-related mortality when using intensive therapy for elderly individuals.
  • Thus, there is a need for new therapeutic approaches to improve the treatment in younger patients and to make AML-directed therapy with acceptable toxicity possible in elderly individuals.
  • Angiogenesis seems to be important both for leukemogenesis and susceptibility to intensive chemotherapy, and antiangiogenic strategies are therefore considered for the treatment of AML.
  • The two proangiogenic mediators vascular endothelial growth factor (VEGF) and interleukin 8, (IL-8, also referred to as CXCL8) seem to be important in human AML: VEGF is released at increased levels due to interactions between AML cells and neighboring nonleukemic cells, whereas IL-8 is released at high levels by native human AML cells.
  • Thus, VEGF as a therapeutic target in AML is suggested both by experimental and clinical observations, whereas IL-8 as a target is mainly suggested by experimental evidence.
  • In the present review we describe and discuss (i) the angioregulatory network of soluble mediators in AML, including both the systemic levels and local release by native human AML cells; and (ii) various therapeutic approaches to target VEGF and IL-8.
  • Although single angioregulatory mediators can be targeted, it should be emphasized that the final effect of soluble mediators on angioregulation is determined by a complex angioregulatory network that varies between AML patients, and the final effect of targeting single mediators may therefore differ between patient subsets.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Interleukin-8 / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975045.001).
  • [ISSN] 1568-0096
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interleukin-8; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 222
  •  go-up   go-down


34. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant; 2007 May;13(5):601-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
  • Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation in chronic myelogenous leukemia compared to sibling donors.
  • We compared outcomes for 105 patients aged 16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected matching set of 105 HLA-matched sibling donor (MSD) transplants.
  • There was no significant difference between URD and MSD controls in the distributions of time from diagnosis to transplant, donor-recipient sex match, prior therapies, donor age, or performance status.
  • Both neutrophil and platelet engraftment were significantly more rapid in the sibling group, but transplant-related mortality at 100 days was not significantly different.
  • There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or above at 100 days.
  • Based on this data, URD allografts should be considered in AML patients without a matched sibling donor.
  • This study provides a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448920.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Natori K, Izumi H, Kaneko K, Ishihara S, Nagase D, Fujimoto Y, Kato M, Umeda M, Kuraishi Y: [Four cases of therapy-related leukemia in multiple myeloma]. Gan To Kagaku Ryoho; 2007 Jan;34(1):121-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of therapy-related leukemia in multiple myeloma].
  • We have experienced 4 cases of therapy-related leukemia (TRL) in 119 patients with multiple myeloma (MM) who had received combination chemotherapy including alkylating agents between 1988 and 1998.
  • All 4 cases were acute myelogenous leukemia, 3 were males and 1 was female.
  • Median age at diagnosis of MM was 60 years, and median time to TRL from diagnosis of MM was 5.5 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Multiple Myeloma / drug therapy. Neoplasms, Second Primary / etiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220686.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; RYH2T97J77 / ranimustine; VB0R961HZT / Prednisone; CHOP protocol; VMCP protocol
  •  go-up   go-down


36. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients &gt; or =60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Apr;12(4):466-71
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
  • The optimal postremission treatment for elderly patients with acute myelogenous leukemia (AML) is presently unknown, but recent studies report the feasibility of autologous stem cell transplantation in this population.
  • To better understand the long-term outcome of autologous transplantation in AML patients > or =60 years of age, we evaluated high-dose chemoradiotherapy preparative conditioning followed by transplantation of peripheral blood progenitor cells procured after a single cycle of cytarabine-based consolidation chemotherapy as postremission therapy in 27 patients aged 60 to 71 years (median age, 65 years) with newly diagnosed AML in first complete remission (CR).
  • Seven patients are alive in continuous CR, 19 died from relapse, and 1 died as a result of treatment-related infection.
  • Leukemia-free survival and overall survival are 10.3 and 13.4 months, respectively.
  • Actuarial leukemia-free and overall survival at 3 years are 25% +/- 9% and 28% +/- 9%, respectively.
  • Our results demonstrate that autologous transplantation of peripheral blood progenitor cells is well tolerated and feasible for patients > or =60 years of age with AML in first CR.
  • Future investigation should focus on a randomized study evaluating a larger group of elderly patients in first CR comparing autologous stem cell transplantation with conventional cytarabine-based consolidation chemotherapy to identify the optimal postremission therapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545730.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


37. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ: Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis; 2008 Dec 15;47(12):1507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
  • BACKGROUND: Invasive aspergillosis (IA) is a leading cause of mortality in patients with acute leukemia.
  • METHODS: In 269 patients treated for acute myelogenous leukemia-myelodysplastic syndrome (AML-MDS) during 2002-2007, evidence of IA was collected using high-resolution computed tomography and galactomannan measurement in bronchoalveolar lavage fluid specimens.
  • Diagnostic and therapeutic IA-related costs, corrected for neutropenia duration, were comprehensively analyzed from a hospital perspective.
  • In patients with IA, the mortality rate 12 weeks after starting antifungal therapy was 22% (16 of 73 patients).
  • Total IA-related costs increased to euro 8360 and euro 15,280 for patients with possible and probable or proven IA, respectively, compared with patients without IA (P<.001).
  • CONCLUSIONS: Early diagnosis and treatment of IA with oral voriconazole result in acceptable mortality rates.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillosis / economics. Drug Therapy / economics. Health Care Costs. Leukemia, Myeloid, Acute / complications


38. Huisman C, Meijer E, Petersen EJ, Lokhorst HM, Verdonck LF: Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant; 2008 Feb;14(2):181-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
  • We analyzed the outcome of RIC HSCT in acute myelogenous leukemia (AML) patients over the age of 40 years.
  • Forty-three AML or high-risk myelodysplastic syndrome (MDS) patients were treated with a fludarabine and low-dose total-body irradiation (TBI)-based pretransplantation regimen.
  • All but 2 AML patients were in complete remission (CR) at the time of transplantation.
  • Sixty percent of patients developed acute graft-versus-host disease (aGVHD), which was grade II in 40% and grade III in 12%.
  • Treatment-related mortality (TRM) was low (9%), total nonrelapse mortality (NRM) was 19%.
  • In conclusion, fludarabine plus low-dose TBI-based RIC HSCT is effective in AML patients over the age of 40 years without active disease at the time of transplant and is associated with low TRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18215778.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


39. Khalil F, Cualing H, Cogburn J, Miles L: The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study. Arch Pathol Lab Med; 2007 Aug;131(8):1281-9
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
  • OBJECTIVE: To study the rate of recovery of bone marrow in patients given myelosuppressive therapy for acute myelogenous leukemia, establish the histologic criteria of recovered marrow, and correlate the recovery pattern with those patients who received a bone marrow transplant by using histology, peripheral blood, immunophenotyping, and computerized morphometry and mathematical slope equation.
  • These patients were divided into 2 groups: 1 group of 28 cases diagnosed with acute myeloid leukemia, the majority treated with cytarabine (Ara-C) infusion for 7 days and daunorubicin intravenously daily for 3 days (7+3 regimen), and the other control group of 23 cases treated with chemotherapy or allogeneic bone marrow transplantation for a variety of hematologic malignancies.
  • The absolute neutrophil and platelet counts for 28 cases were related to histologic recovery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / physiology. Bone Marrow Transplantation. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / physiopathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Biopsy. Blood Cell Count. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Image Processing, Computer-Assisted. Immunophenotyping. Male. Middle Aged. Recovery of Function. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683190.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


40. Middeldorf I, Galm O, Osieka R, Jost E, Herman JG, Wilop S: Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Am J Hematol; 2010 Jul;85(7):477-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).
  • In older patients suffering from acute myelogenous leukemia (AML), aggressive chemotherapy is accompanied with high treatment-related morbidity and mortality.
  • Consequently, a variable response of AML cells to anti-CD33-targeted therapy may be caused by modulation of SOCS3 expression.
  • Twenty-four patients with refractory or relapsed CD33-positive AML received GO as a single agent before or after conventional chemotherapy.
  • Response (RR) and overall survival (OS) were significantly higher in 16 patients receiving chemotherapy before GO (RR 81%, OS 14.8 months) compared to three patients who received GO single agent therapy (RR 33%, OS 7.2 months) or 16 with GO before chemotherapy (RR 0% OS 2.2 months, P = 0.01 for RR and P < 0.001 for OS).
  • [MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. DNA Methylation. Leukemia, Myeloid, Acute / drug therapy. Salvage Therapy / methods. Suppressor of Cytokine Signaling Proteins / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20575043.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / SOCS3 protein, human; 0 / Suppressor of Cytokine Signaling Proteins; 0 / gemtuzumab
  •  go-up   go-down


41. Ubukata H, Katano M, Takemura A, Kasuga T, Motohashi G, Ge L, Tabuchi T: Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case. Surg Today; 2005;35(2):153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia suddenly developing just after surgery for advanced gastric cancer: report of a case.
  • We report a case of acute myelogenous leukemia (AML) developing just after surgery for advanced gastric cancer, before adjuvant chemotherapy was started.
  • Acute myelogenous leukemia was diagnosed by an aspiration biopsy of the bone marrow.
  • If the AML had developed later and had become remarkable during or after adjuvant chemotherapy, the differential diagnosis between de novo and therapy-related leukemia would have been very difficult.
  • Most leukemias that develop during the course of chemotherapy or radiotherapy, or both, are indisputably considered to be therapy-related.
  • Thus, we report the clinical course of this patient with reference to the related literature to warn surgeons of the possibility of this unusual manifestation.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Bone Marrow Cells / pathology. Humans. Male. Postoperative Complications / diagnosis


42. Kim HJ, Choi Y, Min WS, Kim TG, Cho BS, Kim SY, Eom KS, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim CC: The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation; 2007 Nov 15;84(9):1082-91
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia.
  • BACKGROUND: We investigated the influence of killer cell immunoglobulin-like receptor (KIR) genes, based on the genotypes of inhibitory or activating KIR, in stem cell recipients with acute myelogenous leukemia and their human leukocyte antigen-matched sibling donors on acute graft-versus host disease (GVHD) after hematopoietic stem cell transplantation.
  • Specifically, the 2DS2 gene and the 2DS4*003 allele were closely correlated with acute GVHD.
  • The 2DS3-2DS5 dual genes were more often involved in a variety of transplant-related complications.
  • [MeSH-major] Graft vs Host Disease / immunology. Hematopoietic Stem Cell Transplantation. Killer Cells, Natural / immunology. Leukemia, Myeloid, Acute / therapy. Receptors, KIR / immunology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998861.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, KIR
  •  go-up   go-down


43. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED: Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant; 2009 Oct;15(10):1306-13
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
  • Autologous peripheral blood stem/progenitor cell transplantation (APBSCT) has been investigated as a potential therapeutic option to improve outcome in patients with acute myelogenous leukemia (AML).
  • We performed a retrospective analysis on 45 patients aged 21 to 73 years (median 51 years) with de novo AML who underwent APBSCT stratified by age, complete remission status, and cytogenetic risk.
  • In addition, there was no treatment-related mortality (TRM).
  • We conclude that APBSCT is a reasonable and safe intensive consolidation for patients with AML who do not have a suitable HLA-matched donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747639.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM: Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood; 2005 Jul 1;106(1):318-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
  • Previous studies demonstrated that ataxia telangiectasia mutated- and Rad3-related (ATR) kinase and its downstream target checkpoint kinase 1 (Chk1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors.
  • The present study examined the effects of 17-AAG and its major metabolite, 17-aminogeldanamycin (17-AG), on Chk1 levels and cellular responses to cytarabine in human acute myelogenous leukemia (AML) cell lines and clinical isolates.
  • Collectively, these results suggest that treatment with 17-AAG might represent a means of reversing checkpoint-mediated cytarabine resistance in AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RIFABUTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1962 Mar 17;193:1085-6 [14471509.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] J Cell Sci. 2005 Jan 1;118(Pt 1):1-6 [15615778.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1078-87 [15718306.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):14349-55 [15699047.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5952-7 [4053067.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] Science. 2000 May 26;288(5470):1425-9 [10827953.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3929-38 [10845930.001]
  • [Cites] Genes Dev. 2000 Jun 15;14(12):1448-59 [10859164.001]
  • [Cites] Annu Rev Biochem. 1999;68:383-424 [10872455.001]
  • [Cites] Curr Biol. 2000 Dec 14-28;10(24):1565-73 [11137007.001]
  • [Cites] Cancer Control. 2001 Jan-Feb;8(1):62-78 [11176038.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1065-72 [11221834.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1799-804 [11280726.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2945-52 [11306472.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4003-9 [11358818.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4129-39 [11390642.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):913-23 [11535615.001]
  • [Cites] Anal Biochem. 2001 Sep 15;296(2):283-6 [11554725.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):705-11 [11583631.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1537-43 [11587211.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S45-52 [11587367.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3575-83 [11739159.001]
  • [Cites] Blood. 2002 Jan 15;99(2):664-71 [11781252.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1159-66 [11850835.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S55-61 [11927289.001]
  • [Cites] Curr Treat Options Oncol. 2000 Apr;1(1):9-17 [12057057.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3694-703 [12110582.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28364-7 [12077112.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Mol Pharmacol. 2002 Sep;62(3):680-8 [12181445.001]
  • [Cites] Semin Hematol. 2002 Jul;39(3 Suppl 2):4-10 [12214287.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Cancer Treat Rep. 1986 Sep;70(9):1059-65 [3461882.001]
  • [Cites] Blood. 1986 Dec;68(6):1185-95 [3535923.001]
  • [Cites] Blood. 1987 Apr;69(4):1134-40 [3470054.001]
  • [Cites] Blood. 1989 Jan;73(1):24-30 [2910362.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):5870-8 [2790800.001]
  • [Cites] Exp Hematol. 1991 Aug;19(7):669-73 [1893953.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6110-7 [1718594.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 [1933891.001]
  • [Cites] Blood. 1992 Mar 1;79(5):1291-8 [1536952.001]
  • [Cites] Semin Oncol. 1992 Apr;19(2 Suppl 4):31-7 [1553573.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):116-24 [8418222.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1415-20 [8068938.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):346-7 [8090205.001]
  • [Cites] Leukemia. 1995 May;9(5):789-98 [7769841.001]
  • [Cites] Nature. 1995 Jul 6;376(6535):37-43 [7596430.001]
  • [Cites] J Antibiot (Tokyo). 1995 Sep;48(9):1021-6 [7592047.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6045-52 [8521391.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(5):423-8 [8599864.001]
  • [Cites] J Biol Chem. 1996 Jul 12;271(28):16720-4 [8663294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8395-400 [8710882.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41 [8962087.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14559-63 [8962091.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2098-104 [9058732.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39858-66 [12176997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14795-800 [12399544.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1905-7 [12471241.001]
  • [Cites] Mol Pharmacol. 2003 Jan;63(1):232-42 [12488556.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):131-8 [12589030.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):213-7 [12676580.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):247-58 [12676583.001]
  • [Cites] Blood. 2003 Jul 1;102(1):269-75 [12623837.001]
  • [Cites] J Biol Chem. 2003 Jul 4;278(27):24428-37 [12709442.001]
  • [Cites] Ann Oncol. 2003 Aug;14(8):1169-76 [12881371.001]
  • [Cites] N Engl J Med. 2003 Aug 21;349(8):743-52 [12930926.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):407-10 [14508491.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4483-93 [14555522.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):47326-39 [12963734.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):419-24 [14624223.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52572-7 [14570880.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1078-84 [14551138.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18641-7 [14988409.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33759-67 [15175348.001]
  • [Cites] Acta Med Scand. 1965 Sep;178(3):263-80 [5213256.001]
  • [Cites] J Cell Physiol. 1970 Aug;76(1):77-84 [5471041.001]
  • [Cites] Cancer Res. 1970 Nov;30(11):2636-44 [5530558.001]
  • [Cites] Blood. 1971 Jan;37(1):1-5 [5275755.001]
  • [Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5046-50 [6488163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Feb;82(3):790-4 [2858093.001]
  • [Cites] Pharmacol Rev. 1989 Jun;41(2):93-141 [2692037.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):713-23 [12554671.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Feb;228(2):111-33 [12563018.001]
  • [Cites] Cell. 1997 Apr 18;89(2):239-50 [9108479.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3375-80 [9269999.001]
  • [Cites] J Biol Chem. 1997 Sep 19;272(38):23843-50 [9295332.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2121-6 [9310463.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4283-96 [9373239.001]
  • [Cites] Blood. 1998 Feb 1;91(3):991-1000 [9446661.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):169-78 [9815970.001]
  • (PMID = 15784732.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA96780; United States / NCI NIH HHS / CA / R01 CA104378; United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / R01 CA90390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / RNA, Small Interfering; 04079A1RDZ / Cytarabine; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Checkpoint kinase 1
  • [Other-IDs] NLM/ PMC1895127
  •  go-up   go-down


45. Daneshbod Y, Amirghofran Z, Tabei SZ: Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients. Neoplasma; 2005;52(2):109-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
  • The aim of this study is to examine the expression of the bcl-2 protein in a group of patients with AML and its relation to clinical features and response to therapy.
  • Slides from the bone marrow or peripheral blood of 70 patients with AML were assessed for the expression of bcl-2 by immunocytochemistry.
  • Bcl-2 expression showed a prognostic value in our patients indicating that even despite of some differences in treatment regimen, immunocytochemical analysis of this marker is still a simple and inexpensive method for evaluation of prognosis in AML patients.
  • Bcl-2 expression may be related to the expression of differentiation associated markers.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD11 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800708.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD11; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


46. Usuki K, Urabe A, Ikeda Y, Ohashi Y, Mizoguchi H, Takaku F, Japan IL-11 Study Group: A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol; 2007 Jan;85(1):59-69
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.
  • To investigate the efficacy of using recombinant human interleukin 11 (rhIL-11) to reduce the need for platelet transfusions, we performed a randomized, double-blind phase II/III study with 110 acute myelogenous leukemia (AML) patients in the first complete remission.
  • We analyzed infection-related events retrospectively.
  • These results show that rhIL-11 does not reduce the platelet transfusion requirement in AML patients, but the retrospective analysis confirms the previous finding that rhIL-11 reduces infection in patients undergoing chemotherapy.
  • [MeSH-major] Interleukin-11 / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Double-Blind Method. Female. Humans. Infection / drug therapy. Infection / etiology. Male. Middle Aged. Placebos. Platelet Transfusion. Recombinant Proteins / therapeutic use. Retrospective Studies. Stomatitis / drug therapy. Stomatitis / etiology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261503.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Placebos; 0 / Recombinant Proteins
  •  go-up   go-down


47. Kim M, Lee S, Jung CK, Lim J, Cho SG, Kim DW, Kim Y, Han K, Min WS, Kim CC: Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. Int J Lab Hematol; 2008 Dec;30(6):508-12
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
  • We investigated chronic myelogenous leukemia (CML) patients who developed trisomy 8 abnormalities in Philadelphia-negative (Ph-) cells during imatinib mesylate treatment to evaluate the clinical outcome and laboratory features.
  • In conclusion, these results suggest that the emergence of trisomy 8 in Ph- cells is transient and not related to therapy-related myelodysplasia or acute leukemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 8 / drug effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / adverse effects. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects. Trisomy

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983302.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


48. Hallemeier CL, Girgis MD, Blum WG, Brown RA, Khoury HJ, Devine SM, Vij R, Lin HS, DiPersio JF, Adkins DR: Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant; 2006 Jul;12(7):749-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
  • We analyzed outcomes of patients with myelodysplastic syndrome (MDS) or secondary acute myelogenous leukemia (sAML) that were treated at our institution with a reduced intensity conditioning (RIC) regimen of 550-cGy total body irradiation and cyclophosphamide followed by related donor (RD) or unrelated donor (URD) transplantation.
  • Overall, the cumulative incidences of relapse and transplant-related mortality were 27% and 37%, respectively.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods


49. Holstein SA, Stokes JB, Hohl RJ: Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res; 2009 Feb;33(2):344-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
  • Tyrosine kinase inhibitors (TKIs) directed against the Bcr-Abl kinase have revolutionized the treatment of chronic myelogenous leukemia (CML).
  • Clinically, there have been a handful of reports associating imatinib with acute renal failure.
  • Second-generation Bcr-Abl TKIs may influence renal function based on differential inhibition of related tyrosine kinases.
  • [MeSH-major] Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / adverse effects. Renal Insufficiency / chemically induced

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18835038.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


50. Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK: [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Jul;28(7):545-8
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
  • OBJECTIVE: To retrospectively analyze the curative effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelogenous leukemia patients (CML).
  • Transplant-related mortality occurred in 12 patients.
  • Acute graft-versus-host disease (aGVHD) occurred in 18 patients (51.4%), among them 7 patients (20.0%) were of grade III-IV.
  • CONCLUSION: The patients who had transplantation done within 1 year after diagnosis during their first chronic phase of disease and who had low-grade GVHD have better prognosis.
  • Those patients who had III-IV acute GVHD are prone to incorporate severe infection, which was a worse prognostic factor of allo-HSCT for chronic myelogenous leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147125.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M: Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant; 2007 Apr;13(4):454-62
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
  • One hundred twelve acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT.
  • Donors were related (53%) and unrelated (47%).
  • In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV acute GVHD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Therapy, Combination. Female. Humans. Kaplan-Meier Estimate. Male. Melphalan / administration & dosage. Middle Aged. Risk Factors. Survivors. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


52. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE: A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood; 2007 Feb 15;109(4):1387-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
  • Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors.
  • In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML.
  • Early death in the absence of progressive disease was rare, and drug-related nonhematologic serious adverse events were observed in 74 patients (47%).
  • Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7514-26 [10602510.001]
  • [Cites] Invest New Drugs. 1999;17(3):241-58 [10665477.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1268-74 [2475589.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2847-53 [1581898.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3229-32 [8205544.001]
  • [Cites] N Engl J Med. 1995 Jun 22;332(25):1671-7 [7760868.001]
  • [Cites] Blood. 1995 Jul 15;86(2):457-62 [7605984.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1871-7 [10766174.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2318-25 [10873082.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6105-13 [10913192.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30451-7 [10852915.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):131-7 [11196150.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):450-8 [11809695.001]
  • [Cites] Blood. 2002 Jul 1;100(1):29-35 [12070004.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3295-304 [7614464.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5302-9 [7585592.001]
  • [Cites] Cancer Res. 1997 Feb 15;57(4):708-13 [9044849.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2969-77 [9376577.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Oncogene. 1998 Sep 17;17(11 Reviews):1439-45 [9779989.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1090-8 [16435386.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • (PMID = 17082323.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
  • [Other-IDs] NLM/ PMC1794070
  •  go-up   go-down


53. Sanz J, Montesinos P, Saavedra S, Lorenzo I, Senent L, Planelles D, Larrea L, Martín G, Palau J, Jarque I, Martínez J, de la Rubia J, Moscardó F, Martinez D, Gómez I, López M, Sanz MA, Sanz GF: Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant; 2010 Nov;16(11):1589-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.
  • Clinical studies focused on outcomes of umbilical cord blood transplantation (UCBT) for patients with chronic myelogenous leukemia (CML) in need of allogeneic stem cell transplantation and lacking an HLA-matched adult donor are limited.
  • The CI of acute graft-versus-host disease (GVHD) grade II-IV was 61%, that of acute GVHD grade III-IV was 39%, and that of chronic extensive GVHD was 60%.
  • Treatment-related mortality (TRM) was 41% for patients undergoing UCBT while in first or second CP and 100% for patients in AP or BC (P < .01).
  • [MeSH-major] Blood Donors. Cord Blood Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Disease-Free Survival. Female. Graft Rejection / epidemiology. Graft Survival. Graft vs Host Disease / diagnosis. Graft vs Host Disease / epidemiology. Histocompatibility. Humans. Leukocyte Count. Male. Middle Aged. Neutrophils / cytology. Platelet Count. Recurrence. Retrospective Studies. Transplantation Chimera. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20553927.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials.
  • Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2).
  • Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05, P = .02), whereas patients with LOS had similar survival regardless of postremission therapy.
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).
  • In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM.
  • These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


55. Ben-Bassat I, Raanani P, Gale RP: Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant; 2007 Apr;39(8):441-6
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia in chronic lymphocytic leukemia.
  • Immune-mediated anti-leukemia effects, often termed graft-versus-leukemia (GvL), operate after bone marrow or blood cell transplants for acute lymphoblastic leukemia, acute myelogenous leukemia and chronic myelogenous leukemia.
  • Sometimes the magnitude of this anti-leukemia effect exceeds that of high-dose anti-leukemia drugs and radiation and can result in leukemia cure.
  • We analyzed leukemia relapse data after transplants for chronic lymphocytic leukemia (CLL) in this context.
  • However, as most of these data are from studies of allotransplants, it is uncertain whether GvL operates in settings where the anti-leukemia effector cells and target CLL cells are genetically identical except for leukemia-related mutations.
  • These potential limitations have important implications on whether immune therapy of CLL will work in non-allotransplant settings.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Graft vs Host Disease / immunology. Graft vs Leukemia Effect / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322931.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


56. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant; 2006 Jan;37(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
  • We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT.
  • The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3).
  • The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%).
  • The median time between diagnosis and transplantation was 5 months (range, 3-86).
  • The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%).
  • Furthermore, age beyond 40 years resulted in a higher treatment-related mortality (47 vs 7%; P = 0.01).
  • Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and of younger age.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation


57. Claxton DF, Ehmann C, Rybka W: Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol; 2005 Jul;130(2):256-64
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
  • A total of 23 patients with acute myelogenous leukaemia (AML) were treated, with a median age of 59 years (range: 28-72) at transplant.
  • Nine patients were in chemotherapy-refractory progression and seven were primarily refractory to induction therapy.
  • Only two, both recipients of haploidentical cells, have died from transplant-related causes.
  • Although follow up is short, this data suggests that non-myeloablative haematopoietic cell transplantation with sirolimus (rapamycin)-based immunosuppression may provide disease control over several years in some patients with advanced and poor prognosis AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / therapy. Sirolimus / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029454.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


58. Mochiduki Y, Muramoto S: [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone]. Rinsho Ketsueki; 2005 Nov;46(11):1218-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone].
  • The translocation (15;17) is a typical marker of acute promyelocytic leukemia, whereas t(9;22) is predominantly associated with chronic myelogenous leukemia, and seldom with acute myelogenous leukemia.
  • We present a case of therapy-related acute promyelocytic leukemia (t-APL) with a subclone accompanied by karyotype 46, XX, t(9; 22)(q34;q11), t(15 ;17)(q22;11 to approximately 12) at onset.
  • [MeSH-major] Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Leukemia, Promyelocytic, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440807.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


59. Laningham FH, Kun LE, Reddick WE, Ogg RJ, Morris EB, Pui CH: Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology; 2007 Nov;49(11):873-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.
  • INTRODUCTION: During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL).
  • Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord.
  • The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades.
  • METHODS AND RESULTS: In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions.
  • A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy.
  • Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings.
  • Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity.
  • CONCLUSION: Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity.
  • Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy.
  • It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for central nervous system leukemia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1993;11(5):534-53 [8402223.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):152-9 [16317748.001]
  • [Cites] Neuroradiology. 1994 Nov;36(8):652-5 [7862289.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Neuroradiology. 1996 Apr;38(3):264-8 [8741199.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1483-8 [8841024.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17(2):295-310 [8938302.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2191-8 [9395033.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):438-40 [10080582.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2804-11 [11387351.001]
  • [Cites] Neuroradiology. 2001 Jun;43(6):492-5 [11465764.001]
  • [Cites] Neuroradiology. 2002 Jul;44(7):559-67 [12136356.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Cleve Clin J Med. 2004 Aug;71(8):633-7 [15449758.001]
  • [Cites] J Pediatr. 1970 Dec;77(6):1089-91 [4922336.001]
  • [Cites] Neuroradiology. 1978;16:543-6 [284200.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1979 Spring;1(1):21-30 [396790.001]
  • [Cites] Neuroradiology. 1981;22(2):79-84 [6946301.001]
  • [Cites] Blood. 1985 Nov;66(5):1062-7 [3840394.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):252-6 [1734087.001]
  • [Cites] Blood. 1992 Feb 15;79(4):871-5 [1737097.001]
  • [Cites] Neurology. 1993 Mar;43(3 Pt 1):618-20 [8451012.001]
  • [Cites] N Engl J Med. 1993 Jul 29;329(5):314-9 [8321259.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Nov-Dec;25(10):1688-95 [15569732.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):10-5 [15547931.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2216-22 [16804111.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Feb;15(2):300-1 [8192076.001]
  • (PMID = 17924103.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090246-05; United States / NCI NIH HHS / CA / R01 CA090246; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / R01 CA090246-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  • [Other-IDs] NLM/ NIHMS49119; NLM/ PMC2386669
  •  go-up   go-down


60. Afzal S, Ishaqi MK, Dupuis A, Doyle J, Gassas A: Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. Bone Marrow Transplant; 2009 Dec;44(12):799-804
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study.
  • To answer the question whether this is true for AML, we extended our cohort to 207 consecutive children with acute leukemia by adding 71 children with AML who received 75 HSCT's between 1994 and 2005.
  • For the AML cohort, all patients at time of HSCT were in complete morphological remission (CR) except for one patient in CR1, who had 8% blasts in the BM before HSCT.
  • Stem cell sources were: matched sibling donor in 40 patients, mismatched related donor in eight patients, matched unrelated donor in 25 children and two children received cord progenitor stem cells.
  • In AML, absolute lymphocyte count <0.3 x 10(9)/l or >0.3 x 10(9)/l on days 21 and 30 were not predictive of relapse with a hazard ratio at day 21=0.88; P=0.8, and hazard ratio at day 30=0.5; P=0.2.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy. Lymphocytes. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Recovery of Function

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421173.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Ayash LJ, Ratanatharathorn V, Braun T, Silver SM, Reynolds CM, Uberti JP: Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia. Am J Hematol; 2007 Jan;82(1):6-14
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
  • Limited data are available for adults undergoing unrelated donor (URD) BMT for AML using chemotherapy-only preparative regimens.
  • Previous studies incorporated irradiation, included adults and children, and excluded secondary leukemia.
  • Herein we report long-term outcomes for adults with poor-prognostic AML receiving a novel regimen of busulfan (16 mg/kg), cytarabine (8,000 mg/m(2)), and cyclophosphamide (120 mg/kg) (BAC), followed by URD BMT.
  • Adverse features included unfavorable cytogenetics (49%), secondary AML (47%), leukemia at transplant (42%), and extramedullary disease (16%).
  • At time of BMT, 23 were in remission (12 CR1) while 22 had leukemia.
  • Acute and chronic GVHD rates were 44 and 67%, respectively.
  • Seventeen (38%) were disease-free 52 months post-BMT; 13 were leukemia-free (eight CR1) at transplant.
  • Secondary leukemia, cytogenetics, cell dose, and GVHD did not influence outcome.
  • In poor-risk AML, BAC provided cytoreduction comparable to reported TBI-containing regimens, when administered for URD BMT.
  • With decreasing treatment-related mortality, it is justified to proceed early to URD BMT for patients with poor prognostic features.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Leukemia, Myeloid, Acute / therapy. Tissue Donors. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Factor XIII / administration & dosage. Factor XIII / adverse effects. Female. Fibrinogen / administration & dosage. Fibrinogen / adverse effects. Follow-Up Studies. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Thrombin / administration & dosage. Thrombin / adverse effects. Transplantation, Homologous


62. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood; 2006 Dec 1;108(12):3674-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
  • Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).
  • Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.


63. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M: Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood; 2006 Aug 15;108(4):1421-3
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
  • Resistance to imatinib mesylate is an emerging problem in the treatment of chronic myeloid leukemia (CML), often associated with point mutations in the Bcr-Abl kinase domain.
  • Ten imatinib-resistant patients with Bcr-Abl kinase mutations received a transplant: 9 had CML (3 in chronic phase, 4 in accelerated phase, and 2 in blast phase) and 1 had Philadelphia-positive acute lymphocytic leukemia (ALL).
  • All patients engrafted; there were no treatment-related deaths.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Point Mutation. Stem Cell Transplantation
  • [MeSH-minor] Adult. Benzamides. Blast Crisis / genetics. Blast Crisis / metabolism. Blast Crisis / mortality. Blast Crisis / therapy. Disease-Free Survival. Female. Graft Survival / drug effects. Graft Survival / genetics. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / administration & dosage. Pyrimidines / administration & dosage. Recurrence. Salvage Therapy. Transplantation, Homologous. Treatment Outcome


64. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood; 2009 Jan 15;113(3):726-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
  • Survival for patients with acute myeloid leukemia (AML) is limited by treatment-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation (HCT).
  • Natural killer (NK)-cell alloreactivity, determined by donor killer-cell immunoglobulin-like receptors (KIRs) and recipient HLA, correlates with successful HCT for AML.
  • Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: at least 1 B haplotype) would affect outcomes, we genotyped donors and recipients from 209 HLA-matched and 239 mismatched T-replete URD transplantations for AML.
  • B/x donors were associated with a higher incidence of chronic graft-versus-host disease (GVHD; RR: 1.51 [95% CI: 1.01-2.18]; P = .03), but not of acute GVHD, relapse, or TRM.
  • This analysis demonstrates that unrelated donors with KIR B haplotypes confer significant survival benefit to patients undergoing T-replete HCT for AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Am J Transplant. 2008 Jun;8(6):1312-7 [18444913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13483-8 [14597723.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):510-4 [9087412.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1446-51 [15973456.001]
  • [Cites] Hum Immunol. 2005 Jul;66(7):836-41 [16112031.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:259-77 [16323418.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4370-6 [16131567.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):633-45 [16533882.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(6):437-44 [16892071.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:42-5 [17445161.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:92-5 [17445176.001]
  • [Cites] Hum Immunol. 2007 May;68(5):309-23 [17462498.001]
  • [Cites] Clin Exp Immunol. 2007 Jun;148(3):520-8 [17493020.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Immunol. 2007 Jun;123(3):272-80 [17446137.001]
  • [Cites] Immunogenetics. 2007 Jul;59(7):525-37 [17464504.001]
  • [Cites] Blood. 2007 Jul 1;110(1):433-40 [17371948.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):3027-36 [18025129.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Int J Immunogenet. 2008 Feb;35(1):1-8 [18093180.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • (PMID = 18945962.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / P01 111412; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC2628378
  •  go-up   go-down


65. Phan CL, Megat Baharuddin PJ, Chin LP, Zakaria Z, Yegappan S, Sathar J, Tan SM, Purushothaman V, Chang KM: Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia. Cancer Genet Cytogenet; 2008 Jan 1;180(1):60-4
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
  • The Philadelphia (Ph) chromosome, or t(9;22), is the hallmark of chronic myelogenous leukemia (CML).
  • The t(3;21)(q26;q22) is a recurrent chromosomal abnormality in some cases of CML blast phase and in treatment-related myelodysplastic syndrome and acute myeloid leukemia.
  • Amplification or copy number increase of RUNX1 has been reported in childhood acute lymphoblastic leukemia.
  • Our study indicated that the progenitor of CML was BCR-ABL dependent through the amplification of Ph chromosome as a mechanism of resistance to imatinib therapy.
  • [MeSH-major] Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 3. Fusion Proteins, bcr-abl / genetics. Gene Amplification. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068536.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


66. Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A: Outcome of allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia in second complete remission: single center experience. Pediatr Transplant; 2009 Dec;13(8):999-1003
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia in second complete remission: single center experience.
  • We reviewed 26 consecutive patients with AML who were transplanted in second CR2 between 1994 and 2005.
  • Nine patients received related donor, 16 patients received unrelated donors, and one patient received unrelated cord stem cells.
  • Acute grade III-IV and chronic extensive GVHD occurred in eight (30%) and nine (35%) patients, respectively.
  • When entering remission, children with relapsed AML have a reasonable survival with HSCT, but relapse and TRM remain a concern.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032410.001).
  • [ISSN] 1399-3046
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


67. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, Vela-Ojeda J, García-Ruiz-Esparza MA, Manzano C, Karduss A, Sumoza A, de-Souza C, Miranda E, Giralt S, Latin American Cooperative Oncohematology Group: The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant; 2005 Dec;36(12):1043-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study.
  • Using a reduced-intensity stem cell transplantation (RIST) schedule, 24 patients with Philadelphia (Ph1) (+) chronic myelogenous leukemia (CML) in first chronic phase (CP) were prospectively allografted in four Latin American countries: México, Brazil, Colombia and Venezuela, using HLA-identical siblings as donors.
  • A total of 11 patients (46%) developed acute graft-versus-host disease (GVHD), and seven of 23 (30%) developed chronic GVHD.
  • The 100-day mortality was 4.4%, and transplant-related mortality was 8%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stem Cell Transplantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / biosynthesis. Benzamides. Blood Component Removal. Child. Female. Graft vs Host Disease / therapy. Humans. Imatinib Mesylate. Male. Middle Aged. Prospective Studies. Time Factors. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247424.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


68. Kim HJ, Min WS, Eom KS, Cho BS, Kim SY, Bok JN, Kim KS, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Kim CC: Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. Bone Marrow Transplant; 2007 Dec;40(11):1069-74
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia.
  • Little is known about the role of acute GvHD (aGvHD) based on the concept of graft-versus-leukaemia effect (GVLE) after unrelated donor haematopoietic stem cell transplantation (uHSCT).
  • We evaluated 67 uHSCTs performed with multinational unrelated donors for patients with AML.
  • Specifically, high-risk AML patients had a much lower relapse rate when they developed aGvHD (P=0.01), compared with the intermediate-risk group.
  • Therefore, the development of aGvHD after uHSCT in AML patients is closely related to a lower relapse rate, probably in association with GVLE.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922041.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Group Antigens; 0 / HLA Antigens
  •  go-up   go-down


69. Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS: [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):706-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
  • OBJECTIVE: To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial.
  • METHODS: This trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from acute myelogenous leukemia ( AML except M3 type) , acute lymphocytic leukemia ( ALL) , chronic myelogenous leukemia-blast (CML-blast) , totally 155 patients.
  • In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin.
  • The acute myelogenous leukemia regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles.
  • The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
  • Drug-related death was observed in 3 of 77 patients in the domestic idarubicin group (3.9%) due to cerebral hemorrage or septic infection.
  • CONCLUSION: Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Agranulocytosis / chemically induced. Blast Crisis / drug therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Male. Middle Aged. Mucositis / chemically induced. Nausea / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274381.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


70. Le Blanc K, Barrett AJ, Schaffer M, Hägglund H, Ljungman P, Ringdén O, Remberger M: Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant; 2009 Sep;15(9):1108-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.
  • We studied 102 SCT patients with unrelated donor and matched unrelated donors and the relationship between LC30 and outcome in patients with myelogenous leukemia.
  • In multivariate analysis, independent factors associated with high relapse-free survival (RFS) were high LC30, high CD34 cell-dose, and absence of acute graft-versus-host disease (aGVHD) grades II-IV.
  • When analyzed as a continuous variable in multivariate analysis, a higher LC30 was associated with a lower transplant-related mortality (TRM; relative hazard [RH]=0.87, P < .05), higher relapse-free survival (RH=3.42, P=.036), and improved survival (RH=4.53, P=.016, excluding GVHD).
  • Significant risk factors to develop low LC30 was chronic myelogenous leukemia (CML; hazard ratio [HR] 0.73, P=.001), prophylaxis with granulocyte colony-stimulating factor (G-CSF; HR 0.81, P=.02) and aGVHD (HR 0.84, P=.05).
  • These results indicate that LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT for myelogenous malignancies.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocytes / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1739-45 [11535506.001]
  • [Cites] Ann Hematol. 1997 Jan;74(1):1-6 [9031607.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 1998 May 1;91(9):3481-6 [9558408.001]
  • [Cites] Bone Marrow Transplant. 1998 Jul;22(1):73-8 [9678799.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(8):823-30 [10516691.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(8):831-6 [10516692.001]
  • [Cites] Exp Hematol. 2005 May;33(5):505-12 [15850828.001]
  • [Cites] Haematologica. 2005 Jul;90(7):939-48 [15996932.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1390-7 [16732175.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1632-3 [16810198.001]
  • [Cites] Curr Opin Oncol. 2007 Mar;19(2):142-7 [17272987.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1733-8 [17541394.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1216-23 [17889359.001]
  • [Cites] Leukemia. 2009 Jan;23(1):53-8 [18830260.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):874-85 [12786798.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):23-30 [12815474.001]
  • [Cites] Tissue Antigens. 2003 Sep;62(3):243-50 [12956878.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):416-23 [14691124.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):217-24 [15059145.001]
  • [Cites] Transplantation. 2004 Jul 15;78(1):122-7 [15257050.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):301-5 [3552023.001]
  • [Cites] Blood. 1989 May 1;73(6):1729-34 [2653461.001]
  • [Cites] Tissue Antigens. 1992 May;39(5):225-35 [1357775.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1094-101 [8427991.001]
  • [Cites] Eur J Haematol. 1993 Jul;51(1):1-12 [8348938.001]
  • [Cites] Bone Marrow Transplant. 1995 Apr;15(4):619-25 [7655390.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):951-6 [11753550.001]
  • (PMID = 19660724.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA HL006105-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS502458; NLM/ PMC3793397
  •  go-up   go-down


71. Krug U, Serve H, Müller-Tidow C, Mesters RM, Steffen B, Büchner T, Berdel WE: New molecular therapy targets in acute myeloid leukemia. Recent Results Cancer Res; 2007;176:243-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New molecular therapy targets in acute myeloid leukemia.
  • Despite improvements to acute myelogenous leukemia (AML) therapy during the last 25 years, the majority of patients still succumb to the disease.
  • The present chapter focuses on exciting areas of research in the field of AML therapy, including promising results with regards to recent improvements in our understanding of angiogenesis, tyrosine kinase signaling, farnesylation, cell cycling, modulation of gene expression, protein degradation, modulation of intracellular proteins, apoptosis, metabolism, and the possible retargeting of oncogenic proteins.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Leukemia, Myeloid / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Cell Cycle / drug effects. Gene Expression / drug effects. Humans. Oncogenes / drug effects. Proteins / drug effects. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607931.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proteins; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 145
  •  go-up   go-down


72. Klymenko SV, Bink K, Trott KR, Bebeshko VG, Bazyka DA, Dmytrenko IV, Abramenko IV, Bilous NI, Zitzelsberger H, Misurin AV, Atkinson MJ, Rosemann M: MLL gene alterations in radiation-associated acute myeloid leukemia. Exp Oncol; 2005 Mar;27(1):71-5
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLL gene alterations in radiation-associated acute myeloid leukemia.
  • AIM: Although acute myelogenous leukemia (AML) arising after radiation exposure is considered to be secondary, little is known about the molecular mechanisms by which the radiation induces the leukemogenic phenotype.
  • The aim of the study was to analyze whether the MLL translocations are as frequent in radiation-associated AML as in spontaneous AML cases.
  • METHODS: Sixty one AML samples obtained at diagnosis were analyzed for the presence of MLL abnormalities using fluorescent in situ hybridization and/or reverse transcription polymerase chain reaction.
  • Of these patients, 27 had experienced radiation exposure due to the Chernobyl accident, 32 were non-irradiated (spontaneous AML), and 2 developed therapy-related AML after chemotherapy with topoisomerase II inhibitors.
  • RESULTS: MLL gene translocations were detected in both groups of spontaneous and therapy-related AML (1/32 and 1/2 cases respectively).
  • The sole MLL rearrangement found in the group of radiation-associated AML patients was a duplication of the gene.
  • CONCLUSION: Our data preclude the involvement of MLL gene translocations in radiation-induced leukemogenesis, but support the assumption that loss and gain of chromosomal material could be crucial in the leukemogenesis of AML patients with the history of radiation exposure due to the Chernobyl accident.
  • [MeSH-major] Chernobyl Nuclear Accident. Chromosome Aberrations / radiation effects. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812362.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


73. Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ: Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res; 2005 Jun 1;11(11):4225-33
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
  • In this study, we sought to identify and optimize drug partners for binary and tertiary combinations with gemcitabine for use in the treatment of acute myelogenous leukemia (AML).
  • The combination index method was used to evaluate combinations of gemcitabine with fludarabine, paclitaxel, chlorambucil, doxorubicin, mitoxantrone, and SN-38 in U937 human AML cells.
  • Mechanisms underlying interactions related to cell cycle effects and apoptosis were assessed by flow cytometric and caspase-3 and -7 assays, respectively.
  • These findings provided a rationale for clinical trials of gemcitabine + fludarabine and gemcitabine + mitoxantrone where responses were observed in heavily pretreated AML patients.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Deoxycytidine / analogs & derivatives. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Apoptosis / drug effects. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Caspase 3. Caspase 7. Caspases / metabolism. Cell Cycle / drug effects. Chlorambucil / pharmacology. Dose-Response Relationship, Drug. Doxorubicin / pharmacology. Drug Evaluation, Preclinical / methods. Drug Interactions. Enzyme Activation / drug effects. Flow Cytometry. Humans. Mitoxantrone / pharmacology. Paclitaxel / pharmacology. U937 Cells. Vidarabine / analogs & derivatives. Vidarabine / pharmacology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930361.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 18D0SL7309 / Chlorambucil; 7673326042 / irinotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BZ114NVM5P / Mitoxantrone; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP7 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


74. Gutman JA, Leisenring W, Appelbaum FR, Woolfrey AE, Delaney C: Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. Biol Blood Marrow Transplant; 2009 Sep;15(9):1122-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis.
  • Numerous studies confirm the presence of a graft-versus-leukemia (GVL) effect following CBT, and preliminary data suggests that double-unit CBT may be associated with a decreased risk of relapse.
  • We have observed a low relapse rate following CBT among patients with acute leukemias in morphologic complete remission (CR) at the time of myeloablative (MA) transplant.
  • Thirty-one consecutive CBT patients (aged 0.6-42 years, median 22 years), transplanted between April 2006 and June 2008, were compared to matched subjects selected on the basis of disease type and remission number, cytogenetic risk status, minimal residual disease status (MRD), time from diagnosis to first relapse (for patients beyond CR1), use of imatinib for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) patients, age, and date of transplant.
  • Treatment-related mortality (TRM) between cohorts is comparable.
  • Although we have observed a high incidence of acute graft-versus-host disease (aGVHD) following CBT, the incidence of National Institutes of Health (NIH) consensus criteria chronic GVHD (cGVHD) has been low.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 May 15;97(10):2957-61 [11342417.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1660-5 [2015394.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1343-7 [15466923.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):149-60 [15682076.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1322-30 [17038536.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):444-53 [17382250.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64 [17531775.001]
  • [Cites] Lancet. 2007 Jun 9;369(9577):1947-54 [17560447.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Oct;13(10):1145-52 [17889350.001]
  • [Cites] Blood. 2007 Oct 15;110(8):3064-70 [17569820.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4318-27 [18723429.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5183-91 [18768435.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400 [19041062.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2193-200 [18754029.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):256-63 [19064984.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):377-84 [19064980.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1375-82 [18988865.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2410-5 [18997171.001]
  • [Cites] Blood. 1990 Nov 1;76(9):1867-71 [2224134.001]
  • (PMID = 19660726.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA009515-24; United States / NCI NIH HHS / CA / T32 CA009515; United States / NCI NIH HHS / CA / T32 CA 009515-24; United States / NCI NIH HHS / CA / T32 CA009515-24
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS119965; NLM/ PMC2723722
  •  go-up   go-down


75. Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ: Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol; 2005 Oct 1;23(28):7032-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
  • However, it is not known how specific post-transplantation events (acute or chronic graft-versus-host disease [GVHD], treatment-related mortality [TRM], and relapse) may explain mortality differences.
  • PATIENTS AND METHODS: We identified 3,028 patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myeloid leukemia reported to the International Bone Marrow Transplant Registry between 1990 and 2000 who received an HLA-identical sibling HSCT after a myeloablative conditioning regimen in the United States.
  • RESULTS: No statistically significant differences in the risk of acute or chronic GVHD, TRM, or relapse were found between whites and any ethnic minority group.
  • CONCLUSION: The higher risks of treatment failure and mortality among Hispanics may be the net result of modest but not statistically significant increases in both relapse and TRM and cannot be accounted for by any single transplantation-related complication.
  • [MeSH-major] Ethnic Groups. Hematopoietic Stem Cell Transplantation. Hispanic Americans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Graft vs Host Disease / epidemiology. Graft vs Host Disease / ethnology. Humans. Infant. Infant, Newborn. Male. Middle Aged. Minority Groups. Retrospective Studies. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145067.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


76. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M: Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer; 2007 Jul 15;110(2):340-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
  • BACKGROUND: Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate.
  • It is unknown whether the use of these NTKIs before HSCT increases transplant-related toxicity.
  • RESULTS: The median time on treatment was 134 days, and the median time from the end of NTKI therapy to HSCT was 34 days.
  • There was no significant early transplant-related toxicity.
  • Acute and chronic graft-versus-host disease (GVHD) was observed in 7 and 6 patients, respectively.
  • CONCLUSIONS: Previous treatment with NTKI did not increase transplant-related toxicity in this preliminary experience.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Dasatinib. Female. Humans. Male. Middle Aged


77. Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia: High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia; 2006 Mar;20(3):400-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
  • Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive acute leukemias.
  • Thirty-one patients (18 relapsing or refractory Ph+ acute lymphoblastic leukemias and 13 lymphoid blast crisis chronic myelogenous leukemias) were enrolled.
  • Fungus infections were observed in six patients out of 31 and possibly related to dexamethasone.
  • Patients older than 55 years experienced a 90% CR rate without additional toxicities, suggesting the DIV regimen may also be proposed as a front line therapy in older patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


78. Wong SF: Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia. J Oncol Pharm Pract; 2009 Mar;15(1):17-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
  • INTRODUCTION: Imatinib resistance has emerged as a significant clinical issue in the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL).
  • Aside from hematologic events, the most common drug-related toxicities (mostly grade 1-2) in dasatinib clinical trials were fluid retention (including pleural effusion), diarrhea, skin rash, headache, hemorrhage, fatigue, nausea and dyspnea.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Thiazoles / administration & dosage

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753186.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  • [Number-of-references] 55
  •  go-up   go-down


79. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman S, Read EJ, Childs R, Barrett AJ: Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood; 2006 Feb 15;107(4):1688-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.
  • Eighty patients with chronic myeloid leukemia (CML) underwent T cell-depleted stem cell transplantation from an HLA-identical sibling, with add-back of donor T cells on days 30 to 45 and days 60 to 100 in patients in whom grade 2 or greater acute graft-versus-host disease (GVHD) developed.
  • The outcomes for 54 patients with chronic-phase (CP) and 26 with advanced-phase (AP) disease were as follows: overall survival, 85% +/- 5% versus 36% +/- 10%; transplantation-related mortality (TRM), 13% +/- 5% versus 43% +/- 11%; and current leukemia-free survival, 76% +/- 6% versus 34% +/- 9%.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Lymphocyte Count. Lymphocyte Depletion. Stem Cell Transplantation. T-Lymphocytes / immunology. Transplantation, Homologous / immunology


80. Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J: A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant; 2008 Jun;41(11):941-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center.
  • We reviewed 70 consecutive children with AML who received hematopoietic stem cell transplantation (HSCT) in our institution between 1994 and 2005.
  • Most patients transplanted in CR1 (81%) received related donor HSCT, whereas most of the CR2 patients (74%) received unrelated donor HSCT.
  • Expectedly, there was a significant increase in acute GVHD incidence in CR2 patients (40 vs 25% for grades I-II and 30 vs 10% for grades III-IV; P=0.02) and a significant increase in transplant-related mortality (38 vs 11%; P=0.01).
  • Children with relapsed AML who achieve and maintain remission until HSCT, have a reasonable survival, but the outcome of children receiving HSCT in CR1 remains superior.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264141.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS: Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant; 2007 Jun;39(12):751-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
  • Allogeneic stem cell transplantation (ASCT) has improved leukemia-free survival (LFS) in many but not all patients with acute leukemia.
  • This is an eight-year follow-up to our previous study showing a survival advantage to patients with an increased gammadelta T cells following ASCT. gammadelta T cell levels were collected prospectively in 153 patients (acute lymphoblastic leukemia (ALL) n = 77; acute myelogenous leukemia (AML) n = 76) undergoing partially mismatched related donor ASCT.
  • In conclusion, gammadelta T cells may facilitate a graft-versus-leukemia (GvL) effect, without causing GvHD.
  • Further evaluations of this effect may lead to specific immunotherapy for patients with refractory leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptors, Antigen, T-Cell, gamma-delta / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17450185.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA 76667
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


82. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW: A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother; 2007 Nov;8(16):2775-87
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is a rare, high-risk, aggressive form of acute leukemia, affecting primarily adults and the elderly.
  • Patients with high-risk forms of ALL typically have extremely poor prognosis and incur high disease-related costs.
  • Successful use of imatinib in patients with Ph+ chronic myelogenous leukemia (CML) has led to the administration of imatinib in recent clinical studies for patients with Ph+ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956198.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 70
  •  go-up   go-down


83. Perini GF, Santos FP, Funke V, Ruiz J, Neto BH, Hamerschlak N: Nilotinib post-liver transplantation for acute hepatic failure related to imatinib. Leuk Res; 2009 Dec;33(12):e234-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.
  • This is the case report of a 47-year-old woman referred to our institution due to acute liver failure related to imatinib, who was submitted to a successful liver transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Liver Failure, Acute / chemically induced. Liver Transplantation. Piperazines / adverse effects. Pyrimidines / adverse effects. Pyrimidines / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632720.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


84. Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D: t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer; 2006 Apr 15;106(8):1730-8
Hazardous Substances Data Bank. HYDROXYUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
  • RESULTS: In all 16 patients with chronic myeloproliferative disorders, including 14 with chronic myelogenous leukemia (CML), the occurrence of t(3;21) heralded myeloid blast transformation.
  • Among 10 cases of t(3;21)-associated acute myeloid leukemia, 8 were secondary tumors after chemotherapy for other neoplasms that had been treated with regimens including fludarabine and 5-fluorouracil in 3 patients each and etoposide in 2 patients.
  • Among patients with acute myeloid leukemia/myelodysplastic syndrome, 7 died of disease (at a median of 2 mos) and 2 had persistent leukemia with short follow-up.
  • CONCLUSIONS: Activation of AME through t(3;21) defines a highly aggressive, therapy-related leukemic blast syndrome.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 21 / drug effects. Chromosomes, Human, Pair 3 / drug effects. Hydroxyurea / adverse effects. Leukemia, Myeloid / chemically induced. Leukemia, Myeloid / genetics. Lymphocyte Activation / drug effects. Myeloproliferative Disorders / drug therapy. Oncogene Proteins, Fusion / analysis. Translocation, Genetic / drug effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16532439.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; 0 / Transcription Factors; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


85. Kaufmann SH, Steensma DP: On the TRAIL of a new therapy for leukemia. Leukemia; 2005 Dec;19(12):2195-202
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the TRAIL of a new therapy for leukemia.
  • The cytokine TRAIL (tumor necrosis factor alpha-related apoptosis-inducing ligand) as well as agonistic antibodies that bind to the TRAIL receptors, death receptor 4 (DR4) and DR5, are undergoing preclinical and early clinical evaluation as potential therapeutic agents for a variety of hematological and nonhematological malignancies.
  • Here, we briefly review the normal biological function of TRAIL, the mechanism of cytotoxicity of TRAIL receptor ligands, and their effects on normal myeloid progenitors, myelodysplastic marrow and leukemic cells, including acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL), in vitro.
  • [MeSH-major] Apoptosis Regulatory Proteins / physiology. Leukemia / pathology. Membrane Glycoproteins / physiology. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Apoptosis. Humans. Ligands. Receptors, Tumor Necrosis Factor / physiology. TNF-Related Apoptosis-Inducing Ligand

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16224489.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA69008
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha
  • [Number-of-references] 121
  •  go-up   go-down


86. Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA: Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplant; 2008 Nov;42(10):659-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
  • Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is allo-SCT.
  • A retrospective review was performed of 24 patients who underwent related- or unrelated-donor SCT for t-MDS/t-AML at our institution.
  • EFS was 40% in Alk/RT-related t-MDS/t-AML and 11% in Topo II-related t-MDS/t-AML (P=0.05), with an increased risk of relapse in the latter (56 vs 29%, respectively (P=0.05)).
  • In multivariate analysis, development of acute GVHD (P=0.009) and Topo II-related t-MDS/t-AML (P=0.018) were associated with inferior EFS.
  • Patients with acute GVHD had an increased risk of NRM (P=0.03) whereas risk of relapse was higher for patients of advanced age (P=0.046) and for patients who underwent bone marrow (vs blood) SCT (P=0.032).
  • Allo-SCT can result in long-term survival for individuals with t-MDS/t-AML although outcome in Topo II-related t-MDS/t-AML patients remains suboptimal.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myeloablative Agonists / adverse effects. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy


87. Wang LH, Wang M, Zhou CL, Chen S, Zhang XW, Xing HY, Wang JX: [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2005 Jun;26(6):335-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
  • OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in acute leukemia patients and its clinical implication.
  • METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of acute myeloid leukemia (AML), 25 acute lymphocytic leukemia (ALL), 2 acute hybrid leukemia (AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic myelogenous leukemia in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations.
  • RESULTS: Among AML patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P < 0.01).
  • The presence of TKD mutations was related neither to age, sex, nor to WBC counts, the marrow blast percentages, and CR rates for induction therapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185475.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


88. Kunitomi A, Ishikawa T, Tajima K, Konaka Y, Yagita M: Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia. Int J Hematol; 2006 Apr;83(3):262-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia.
  • We describe a patient with Wegener granulomatosis (WG) who underwent long-term cyclophosphamide treatment and thereafter developed acute myelogenous leukemia (AML).
  • After the AML was induced into remission, the patient received an allogeneic stem cell transplant (allo-SCT) from his sibling after undergoing a reduced-intensity conditioning regimen.
  • No clinically apparent acute or chronic graft-versus-host disease developed.
  • He is now in remission for both AML and WG at 22 months after transplantation.
  • [MeSH-major] Cyclophosphamide / adverse effects. Granulomatosis with Polyangiitis / drug therapy. Immunosuppressive Agents / adverse effects. Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Granulomatosis with Polyangiitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720560.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


89. Porter D, Levine JE: Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol; 2006 Jan;43(1):53-61
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
  • Although dramatically effective for relapsed chronic myelogenous leukemia (CML), successful donor leukocyte infusion (DLI) remains limited primarily by inadequate responses for patients with diseases other than CML and by toxicity related to graft-versus-host disease (GVHD).
  • Acute GVHD grades 2 to 4 follows 34% to 47% of infusions and chronic GVHD occurs in 33% to 61% of cases.
  • Strategies to reduce the incidence and severity of GVHD while preserving the graft-versus-leukemia (GVL) effect, such as low-dose DLI, depletion of GVHD effector cells, and tumor-specific DLI, are reviewed.
  • [MeSH-major] Graft vs Host Disease / etiology. Graft vs Leukemia Effect. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukocyte Transfusion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412789.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


90. Al-Ali H, Cross M, Lange T, Freund M, Dölken G, Niederwieser D: Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S17-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
  • Although much progress has been made in understanding the molecular basis of acute myeloid leukaemia (AML), this has not yet led to major improvements in the overall survival of patients.
  • In particular, the treatment of elderly patients with AML remains one of the major challenges in haematology.
  • Allogeneic stem cell transplantation (SCT) is the most efficient antileukaemic treatment for patients with AML, but eligibility for the treatment was confined for a long time to younger patients.
  • After extensive phase I and phase II studies, associated problems of graft rejection have been largely resolved and transplant-related mortality (TRM) evaluated in more than 3000 patients.
  • TRM does not currently exceed 10-12% in related and 20% in unrelated SCT even in patients up to the age of 75 years, so that relapse after transplantation remains the major problem.
  • Randomized studies are now being initiated to define the role of SCT in the treatment of elderly patients with AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Whole-Body Irradiation / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Chimerism. Combined Modality Therapy. Graft Rejection. Graft vs Leukemia Effect. Humans. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561407.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Yu RX, Zhou YH, Lin SY: [Effects of combined therapy of human leucocyte antigen haploidentical related bone marrow transplantation and Chinese medicine in treating leukaemia]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Jul;26(7):600-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of combined therapy of human leucocyte antigen haploidentical related bone marrow transplantation and Chinese medicine in treating leukaemia].
  • OBJECTIVE: To explore the feasibility of human leucocyte antigen (HLA) haploidentical related T-cell undepleted allogeneic bone marrow transplantation (Allo-BMT) combined with Chinese medicine for the treatment of leukaemia.
  • METHODS: Four patients with chronic myeloblastic leukemia (CML) and 4 with acute myeloid leukemia (AML) received allo-BMT with graft from 1 - 3 HLA-mismatched related donors.
  • CONCLUSION: Combined therapy of HLA haploidentical related T-cell undepleted Allo-BMT and Chinese medicine plus immunosuppressants with pre-harvest G-CSF application in doner could effectively reduce the incidence of acute severe GVHD and raise the disease-free survival rate in treating leukaemia.


92. Oehler VG, Radich JP, Storer B, Blume KG, Chauncey T, Clift R, Snyder DS, Forman SJ, Flowers ME, Martin P, Guthrie KA, Negrin RS, Appelbaum FR, Bensinger W: Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant; 2005 Feb;11(2):85-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
  • Seventy-two chronic myeloid leukemia patients were enrolled as part of a larger randomized trial at 3 centers between March 1996 and July 2001 to undergo either HLA-matched related allogeneic bone marrow (BM) or filgrastim (granulocyte colony-stimulating factor)-mobilized peripheral blood stem cell (PBSC) transplantation.
  • There was no statistically significant difference in the incidence of acute or chronic graft-versus-host disease (GVHD), overall survival, disease-free survival, or non-relapse-related mortality between patients receiving BM or PBSC transplants.
  • The cumulative incidence of grade II to IV acute GVHD was 49% in BM and 55% in PBSC recipients ( P = .48).
  • Among 62 chronic phase chronic myeloid leukemia patients, there was no significant difference in overall survival (87% versus 81%; P = .59), disease-free survival (80% versus 81%; P = .61), or non-relapse-related mortality (13% versus 19%; P = .60) by cell source (BM versus PBSCs).
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Peripheral Blood Stem Cell Transplantation


93. Kara IO, Sahin B, Paydas S, Kara B: Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma; 2005 Jul;46(7):1081-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
  • A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation.
  • Three years following transplantation, masses were evidenced in his heart by echocardiography but had completely disappeared following a common chemotherapy etoposide, mitoxantrone, ara-C (EMA) regimen for relapsed AML.
  • Here we present the case history and related literature has been reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Sarcoma, Myeloid / drug therapy. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Heart Neoplasms / diagnosis. Heart Neoplasms / drug therapy. Heart Neoplasms / etiology. Humans. Male. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


94. Ramamoorthy SK, Pandita R, Prakash A, Ramaswamy NV, Al Bahar S: Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice. Acta Haematol; 2007;118(3):141-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
  • Acute leukemia presenting as cholestatic jaundice is rare.
  • It can occur due to granulocytic sarcoma compressing the bile ducts in case of acute myeloid leukemia.
  • We report a case of chronic myeloid leukemia in lymphoid blast cell crisis presenting with severe cholestatic jaundice due to diffuse infiltration of the liver sinusoids with lymphoblasts.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Blast Crisis / drug therapy. Jaundice, Obstructive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Liver Neoplasms / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Adult. Benzamides. Diagnosis, Differential. Drug-Related Side Effects and Adverse Reactions. Humans. Imatinib Mesylate. Male


95. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ: Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant; 2007 Jun;13(6):655-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
  • Cytogenetics has an important impact on the prognosis of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
  • However, it is unclear whether currently accepted cytogenetic risk groups, which were established for patients treated mostly with standard therapy, are optimally discriminating for patients undergoing HSCT.
  • Also, the impact of cytogenetics in the growing population of patients with therapy-related disease has not been completely elucidated.
  • In this study, we retrospectively analyzed data on 556 patients with AML or MDS transplanted at our institution.
  • We then applied this grouping scheme to the 80 patients with therapy-related disease.
  • Our proposed 3-group cytogenetic classification outperformed the established grouping schemes for both de novo and therapy-related disease.
  • After accounting for cytogenetics, patients with therapy-related AML or MDS had an equivalent outcome to those with de novo disease.
  • This study demonstrates the impact of cytogenetics on the risk of relapse and death for patients with both de novo and therapy-related disease undergoing transplantation; it also emphasizes the necessity of using cytogenetics to stratify patients entering clinical trials, and provides a system for doing so, which can be validated in a multi-institutional database.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1999 Dec;84(12):1085-7 [10586209.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2002 Dec;16(12):2366-78 [12454741.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S45-8 [15124668.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2510-1 [15197216.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):495-500 [15239403.001]
  • [Cites] Blood. 1981 Oct;58(4):759-67 [7272506.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Mar;11(3):332-50 [6704938.001]
  • [Cites] Blood. 1985 Jun;65(6):1364-72 [3857944.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1748-57 [3783201.001]
  • [Cites] Br J Haematol. 1989 May;72(1):45-53 [2736242.001]
  • [Cites] Blood. 1990 Sep 15;76(6):1083-91 [2400804.001]
  • [Cites] Leuk Res. 1992;16(1):43-6 [1732669.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2370-9 [8246025.001]
  • [Cites] Blood Rev. 1994 Mar;8(1):30-6 [8205008.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):203-8 [7581137.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):104-8 [7577615.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2578-85 [9116305.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2931-8 [9376573.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):737-43 [9384475.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1910-7 [9731047.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3128-35 [10506609.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):25-32 [15349754.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):963-71 [10694545.001]
  • (PMID = 17531775.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI029530-14; United States / NIAID NIH HHS / AI / U19 AI 29530; United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NIAID NIH HHS / AI / AI029530-14; United States / NHLBI NIH HHS / HL / P01 HL 070149; United States / NIAID NIH HHS / AI / U19 AI029530
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS25237; NLM/ PMC2743535
  •  go-up   go-down


96. Kaur P, Feldhahn N, Zhang B, Trageser D, Müschen M, Pertz V, Groffen J, Heisterkamp N: Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Mol Cancer; 2007 Oct 25;6:67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
  • Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia.
  • Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl.
  • RESULTS: After transplant of 10,000 highly malignant leukemic cells into compatible recipients, untreated mice succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg nilotinib survived significantly longer.
  • We examined cells from mice that developed leukemia while under treatment for Bcr/Abl kinase domain point mutations but these were not detected.
  • Nilotinib also exhibited impressive anti-leukemia activity in P190 Bcr/Abl transgenic mice that had developed overt leukemia/lymphoma masses and that otherwise would have been expected to die within 7 days.
  • CONCLUSION: These results show that nilotinib has very impressive anti-leukemia activity but that lymphoblastic leukemia cells can become unresponsive to it both in vitro and in vivo through mechanisms that appear to be Bcr/Abl independent.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 1;95(5):1758-66 [10688835.001]
  • [Cites] Blood. 2007 Jul 15;110(2):727-34 [17405907.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2343-55 [11289094.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3342-8 [11369622.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6188-95 [11593427.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1860-2 [11861307.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3334-58 [12032773.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1014-8 [12130516.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7137-46 [12370803.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2190-6 [12399961.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):5995-8 [12414617.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:111-35 [12446421.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2 Suppl 2):69-79 [12783379.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1163-6 [12921956.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1337-54 [14508819.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8255-62 [14614449.001]
  • [Cites] Leukemia. 2004 Jan;18(1):23-8 [14603339.001]
  • [Cites] Leukemia. 2004 Feb;18(2):189-218 [14737178.001]
  • [Cites] Mini Rev Med Chem. 2004 Mar;4(3):285-99 [15032675.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1459-71 [15042680.001]
  • [Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Nature. 1990 Mar 15;344(6263):251-3 [2179728.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4534-9 [1643646.001]
  • [Cites] Cancer Cell. 2005 Feb;7(2):129-41 [15710326.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):172-83 [15719031.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4941-7 [16000593.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1355-61 [15860663.001]
  • [Cites] Cancer. 2005 Sep 15;104(6):1230-6 [16078266.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6688-93 [16618932.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5387-93 [16707466.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1765-9 [16721371.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2542-51 [16775235.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6468-72 [16818614.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1328-33 [16614241.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2332-8 [16772610.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2057-60 [17008892.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Leukemia. 2007 Jan;21(1):178-80 [17082777.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):8-14 [17208428.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2147-55 [17090651.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2623-9 [17312100.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1189-97 [17392819.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5011-5 [17303698.001]
  • [Cites] Immunol Rev. 2000 Jun;175:23-32 [10933588.001]
  • (PMID = 17958915.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090321; United States / NCI NIH HHS / CA / CA 090321
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Pyrimidines; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2169263
  •  go-up   go-down


97. Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E, Nicolini F, Troncy J, Barraco F, Michallet M, Thomas X: A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. Hematology; 2010 Jun;15(3):125-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
  • Dose intensity has been demonstrated to be one determinant for treatment efficacy in younger adults with high-risk (relapsed and refractory) acute myelogenous leukemia.
  • The period of critical neutropenia was relatively short in both phases and the supportive use of pegfilgrastim, although showing a trend toward reduced neutropenic period, did not appear to reduce the risk of infection in this group and may not be a critical requirement for reducing the risk of treatment-related toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / drug therapy. Neutropenia / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20557669.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


98. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S, Shan J, Rios MB, Cortes J: Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood; 2007 Oct 15;110(8):2991-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
  • The development of chromosomal abnormalities (CAs) in the Philadelphia chromosome (Ph)-negative metaphases during imatinib (IM) therapy in patients with newly diagnosed chronic myecloid leukemia (CML) has been reported only anecdotally.
  • One patient developed acute myeloid leukemia (associated with - 7).
  • At last follow-up, 3 patients died from transplantation-related complications, myocardial infarction, and progressive disease and 2 lost cytogenetic response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chromosome Aberrations / drug effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Chronic-Phase / drug therapy. Leukemia, Myeloid, Chronic-Phase / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use


99. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, Radich JP: Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood; 2007 Apr 1;109(7):2791-3
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
  • Relapse occurs frequently after allogeneic hematopoietic cell transplantation (HCT) for treatment of high-risk Philadelphia chromosome-positive (Ph+) leukemia.
  • Administration of imatinib early after HCT might provide an effective approach for preventing recurrent Ph+ leukemia, but the feasibility of this approach has not been systematically tested.
  • Twenty-two patients, 15 with Ph+ acute lymphoblastic leukemia and 7 with high-risk chronic myelogenous leukemia, were enrolled in a prospective study and given imatinib from the time of engraftment until 365 days after HCT.
  • The most common adverse events related to imatinib administration were grade 1-3 nausea, emesis, and serum transaminase elevations.
  • We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):21-36 [11258387.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1469-77 [16638934.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Haematologica. 2003 Feb;88(2):227-9 [12604417.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Mar;9(3):206-12 [12652472.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1707-12 [12970768.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):685-702, x [15271400.001]
  • [Cites] J Clin Invest. 2004 Aug;114(3):379-88 [15286804.001]
  • [Cites] Blood. 1995 May 1;85(9):2632-8 [7727789.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1410-4 [9269758.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Dec;10(12):883-4 [15570257.001]
  • [Cites] Blood. 2005 Jul 15;106(2):458-63 [15817679.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Nat Med. 2006 Feb;12(2):214-9 [16444265.001]
  • [Cites] Nat Med. 2006 Feb;12(2):207-13 [16444266.001]
  • [Cites] N Engl J Med. 2006 May 25;354(21):2282-4 [16723621.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1590-5 [12176876.001]
  • (PMID = 17119111.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / CA18029
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC1852215
  •  go-up   go-down


100. Iastrebner M, Jang JH, Nucifora E, Kim K, Sackmann F, Kim DH, Orlando S, Jung CW, Basquiera A, Klein G, Santini F, Bernard HI, Korin J, Taborda G: Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leuk Lymphoma; 2010 Dec;51(12):2250-7
Hazardous Substances Data Bank. AZACITIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.
  • This multicenter, open-label study evaluated the efficacy and safety of decitabine in patients from Argentina and South Korea with myelodysplastic syndromes or chronic myelomonocytic leukemia.
  • Treatment-related adverse events included febrile neutropenia, thrombocytopenia and bleeding, asthenia, fatigue, and eosinophilia.
  • Acute myelogenous leukemia developed during follow-up in 21% of patients.
  • [MeSH-major] Azacitidine / analogs & derivatives. Leukemia, Myelomonocytic, Chronic / drug therapy. Myelodysplastic Syndromes / drug therapy






Advertisement